|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions affects localization |
ISO |
A 77636 binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [A 77636 affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [A 77636 results in increased activity of DRD1 protein] |
CTD |
PMID:15985612 |
|
NCBI chr17:11,099,736...11,104,352
Ensembl chr17:11,101,306...11,103,541
|
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Duloxetine Hydrochloride binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of CYP17A1 protein Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Pregnenolone] which results in increased chemical synthesis of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased hydroxylation of Progesterone] which results in increased chemical synthesis of 17-alpha-Hydroxyprogesterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone] which results in increased chemical synthesis of Dehydroepiandrosterone]; Duloxetine Hydrochloride inhibits the reaction [[CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] which results in increased chemical synthesis of Androstenedione]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Pregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased hydroxylation of Progesterone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxypregnenolone]; Duloxetine Hydrochloride inhibits the reaction [CYP17A1 protein results in increased metabolism of 17-alpha-Hydroxyprogesterone] |
CTD |
PMID:29100959 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[furafylline results in decreased activity of CYP1A2 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP1A2 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride; CYP2D6 protein results in increased activity of and results in increased glutathionylation of Duloxetine Hydrochloride |
CTD |
PMID:20669986 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of HMOX1 mRNA |
CTD |
PMID:29134401 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Duloxetine Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnj3 |
potassium inwardly-rectifying channel, subfamily J, member 3 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA]; Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 3:41,019,898...41,181,070
Ensembl chr 3:41,019,898...41,181,070
|
|
G |
Kcnj5 |
potassium inwardly-rectifying channel, subfamily J, member 5 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ5 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr 8:33,435,493...33,463,410
Ensembl chr 8:33,433,905...33,463,467
|
|
G |
Kcnj6 |
potassium inwardly-rectifying channel, subfamily J, member 6 |
multiple interactions |
ISO |
Duloxetine Hydrochloride results in decreased activity of [KCNJ3 mRNA co-treated with KCNJ6 mRNA] |
CTD |
PMID:22164246 |
|
NCBI chr11:35,011,007...35,262,362
Ensembl chr11:35,024,196...35,099,383
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
affects localization |
ISO |
Duloxetine Hydrochloride affects the localization of NFE2L2 protein |
CTD |
PMID:29134401 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Prl |
prolactin |
increases expression |
ISO |
Duloxetine Hydrochloride results in increased expression of PRL protein |
CTD |
PMID:17606668 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to 1-(3-chlorophenyl)piperazine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine; [1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Apomorphine]; tertatolol inhibits the reaction [[1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride binds to and results in increased activity of HTR1A protein] which results in decreased susceptibility to Physostigmine] |
CTD |
PMID:8539317 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases response to substance |
ISO |
BAX protein results in increased susceptibility to Acridine Orange |
CTD |
PMID:16177561 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Acridine Orange binds to Platinum Compounds] which results in increased expression of GSTP1 mRNA; [Acridine Orange binds to Platinum] which results in increased expression of GSTP1 mRNA |
CTD |
PMID:16814760 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
Acridine Orange results in increased stability of and results in increased activity of TP53 protein |
CTD |
PMID:16177561 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases hydroxylation |
ISO |
CYP2D6 protein results in increased hydroxylation of Atomoxetine Hydrochloride |
CTD |
PMID:17470523 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions increases expression |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein] Benzophenoneidum results in increased expression of ALDH1A1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:238,222,689...238,264,381
Ensembl chr 1:238,222,521...238,264,330
|
|
G |
Ano6 |
anoctamin 6 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ANO6 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:137,142,063...137,335,208
Ensembl chr 7:137,142,170...137,335,208
|
|
G |
Araf |
A-Raf proto-oncogene, serine/threonine kinase |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ARAF protein |
CTD |
PMID:28722353 |
|
NCBI chr X:1,369,534...1,391,603
Ensembl chr X:1,379,194...1,390,873
|
|
G |
Atp6ap2 |
ATPase H+ transporting accessory protein 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of ATP6AP2 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:11,137,889...11,164,854
Ensembl chr X:11,136,939...11,164,915
|
|
G |
Ccdc22 |
coiled-coil domain containing 22 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC22 protein |
CTD |
PMID:28722353 |
|
NCBI chr X:15,742,978...15,754,925
Ensembl chr X:15,742,978...15,754,925
|
|
G |
Ccdc39 |
coiled-coil domain containing 39 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CCDC39 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:120,278,605...120,367,829
Ensembl chr 2:120,278,605...120,316,600
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CD44 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CHTF18 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:15,090,762...15,098,825
Ensembl chr10:15,090,316...15,098,791
|
|
G |
Commd1 |
copper metabolism domain containing 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COMMD1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:107,664,321...107,759,974
Ensembl chr14:107,664,255...107,760,191
|
|
G |
Cops7b |
COP9 signalosome subunit 7B |
increases expression |
ISO |
Benzophenoneidum results in increased expression of COPS7B protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:93,607,199...93,633,064
Ensembl chr 9:93,607,477...93,633,064
|
|
G |
Cul3 |
cullin 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of CUL3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:86,044,485...86,129,066
Ensembl chr 9:86,044,485...86,129,329
|
|
G |
Dynlt1 |
dynein light chain Tctex-type 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of DYNLT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:47,206,892...47,213,785
Ensembl chr 1:47,206,895...47,213,749
|
|
G |
Eif4g3 |
eukaryotic translation initiation factor 4 gamma, 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of EIF4G3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:156,343,663...156,564,037
Ensembl chr 5:156,396,695...156,564,037
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of FASTKD2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:70,448,386...70,471,420
Ensembl chr 9:70,450,444...70,470,550
|
|
G |
Hook3 |
hook microtubule-tethering protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HOOK3 protein |
CTD |
PMID:28722353 |
|
NCBI chr16:70,710,347...70,818,789
|
|
G |
Hsd17b7 |
hydroxysteroid (17-beta) dehydrogenase 7 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HSD17B7 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:88,288,116...88,308,019
Ensembl chr13:88,288,046...88,307,988
|
|
G |
Htt |
huntingtin |
increases expression |
ISO |
Benzophenoneidum results in increased expression of HTT protein |
CTD |
PMID:28722353 |
|
NCBI chr14:81,105,139...81,254,637
Ensembl chr14:81,105,139...81,254,637
|
|
G |
Iqgap3 |
IQ motif containing GTPase activating protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of IQGAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:187,447,477...187,489,630
Ensembl chr 2:187,447,501...187,489,630
|
|
G |
Kifap3 |
kinesin-associated protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of KIFAP3 protein |
CTD |
PMID:28722353 |
|
NCBI chr13:82,072,497...82,217,256
Ensembl chr13:82,072,497...82,217,252
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
ALDH1A1 protein promotes the reaction [Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein]; Benzophenoneidum results in increased lipidation of and results in increased cleavage of MAP1LC3B protein |
CTD |
PMID:28722353 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Map2k4 |
mitogen activated protein kinase kinase 4 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MAP2K4 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:52,196,121...52,301,887
Ensembl chr10:52,196,124...52,290,657
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of MBD3 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:12,179,046...12,186,251
Ensembl chr 7:12,179,203...12,186,656
|
|
G |
Noa1 |
nitric oxide associated 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NOA1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:33,107,868...33,124,172
Ensembl chr14:33,108,024...33,124,171
|
|
G |
Nup62 |
nucleoporin 62 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of NUP62 protein |
CTD |
PMID:28722353 |
|
NCBI chr 1:100,811,140...100,827,119
Ensembl chr 1:100,811,755...100,827,111
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PLCG1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 3:156,727,642...156,758,307
Ensembl chr 3:156,727,642...156,758,307
|
|
G |
Ppp4r1 |
protein phosphatase 4, regulatory subunit 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PPP4R1 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:113,515,312...113,573,308
Ensembl chr 9:113,534,326...113,573,307
|
|
G |
Prim2 |
DNA primase subunit 2 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRIM2 protein |
CTD |
PMID:28722353 |
|
NCBI chr 9:38,535,435...38,745,058
Ensembl chr 9:38,536,920...38,745,099
|
|
G |
Prom1 |
prominin 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PROM1 protein |
CTD |
PMID:28722353 |
|
NCBI chr14:71,532,321...71,637,400
Ensembl chr14:71,533,063...71,637,417
|
|
G |
Prorp |
protein only RNase P catalytic subunit |
increases expression |
ISO |
Benzophenoneidum results in increased expression of PRORP protein |
CTD |
PMID:28722353 |
|
NCBI chr 6:76,079,880...76,171,298
Ensembl chr 6:76,079,880...76,171,296
|
|
G |
Shmt1 |
serine hydroxymethyltransferase 1 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SHMT1 protein |
CTD |
PMID:28722353 |
|
NCBI chr10:47,030,813...47,059,216
Ensembl chr10:47,031,050...47,059,216
|
|
G |
Srsf11 |
serine and arginine rich splicing factor 11 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of SRSF11 protein |
CTD |
PMID:28722353 |
|
NCBI chr 2:264,837,463...264,864,296
Ensembl chr 2:264,837,472...264,864,265
|
|
G |
Tbc1d15 |
TBC1 domain family, member 15 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TBC1D15 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:58,164,190...58,219,804
Ensembl chr 7:58,164,198...58,219,790
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Benzophenoneidum results in increased expression of TFAM protein |
CTD |
PMID:28722353 |
|
NCBI chr20:18,594,057...18,606,106
Ensembl chr20:18,594,037...18,606,151
|
|
G |
Usp24 |
ubiquitin specific peptidase 24 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of USP24 protein |
CTD |
PMID:28722353 |
|
NCBI chr 5:125,896,725...126,030,411
Ensembl chr 5:125,896,725...126,030,401
|
|
G |
Washc5 |
WASH complex subunit 5 |
increases expression |
ISO |
Benzophenoneidum results in increased expression of WASHC5 protein |
CTD |
PMID:28722353 |
|
NCBI chr 7:99,625,379...99,677,237
Ensembl chr 7:99,625,619...99,677,268
|
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
Colesevelam Hydrochloride results in decreased expression of CRP protein |
CTD |
PMID:16616026 |
|
NCBI chr13:91,080,448...91,081,358
Ensembl chr13:91,054,974...91,093,713
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions increases expression |
ISO |
Colesevelam Hydrochloride promotes the reaction [Simvastatin results in increased expression of HMGCR mRNA] Colesevelam Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Ldlr |
low density lipoprotein receptor |
increases expression |
ISO |
Colesevelam Hydrochloride results in increased expression of LDLR mRNA |
CTD |
PMID:22120639 |
|
NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions increases expression |
ISO |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [Doxorubicin results in increased expression of ABCB4 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in decreased expression of ABCB4 mRNA] |
CTD |
PMID:12926078 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Colforsin results in increased expression of ABCC2 mRNA; Colforsin results in increased expression of ABCC2 protein |
CTD |
PMID:19580841 PMID:26049102 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ABCG2 mRNA Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] |
CTD |
PMID:19580841 PMID:30610963 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of ACACA protein |
CTD |
PMID:18390901 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression |
EXP |
Colforsin results in increased activity of ACHE protein; Colforsin results in increased activity of ACHE protein alternative form Colforsin results in increased expression of ACHE mRNA |
CTD |
PMID:18514641 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
increases expression |
ISO |
Colforsin results in increased expression of ACSL3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 9:84,569,601...84,593,565
Ensembl chr 9:84,569,597...84,593,565
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
ISO EXP |
Colforsin results in decreased expression of ACTA2 protein Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:21603974 PMID:27590029 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adam12 |
ADAM metallopeptidase domain 12 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAM12 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 1:205,951,840...206,286,294
Ensembl chr 1:205,956,342...206,282,575
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
|
|
G |
Adcy5 |
adenylate cyclase 5 |
multiple interactions |
ISO |
ADCY5 protein results in increased susceptibility to [Colforsin co-treated with Quinpirole] |
CTD |
PMID:12223546 |
|
NCBI chr11:68,695,839...68,842,452
Ensembl chr11:68,695,839...68,842,320
|
|
G |
Adcy6 |
adenylate cyclase 6 |
affects response to substance |
ISO |
ADCY6 protein affects the susceptibility to Colforsin |
CTD |
PMID:12393090 |
|
NCBI chr 7:140,270,678...140,291,722
Ensembl chr 7:140,270,692...140,291,620
|
|
G |
Adcy9 |
adenylate cyclase 9 |
multiple interactions increases activity |
ISO |
[Colforsin co-treated with Miconazole] results in increased activity of ADCY9 protein Colforsin results in increased activity of ADCY9 protein |
CTD |
PMID:30607468 |
|
NCBI chr10:11,392,698...11,515,406
Ensembl chr10:11,392,625...11,512,600
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
ISO |
[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] affects the reaction [[Phenylephrine binds to and results in increased activity of ADRA1A protein] which affects the transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions affects localization increases expression |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA] |
CTD |
PMID:24701590 |
|
NCBI chr14:80,730,307...80,732,010
Ensembl chr14:80,730,307...80,732,010
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects response to substance multiple interactions |
ISO |
ADRB1 protein polymorphism affects the susceptibility to Colforsin [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] |
CTD |
PMID:14502278 PMID:19419905 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression increases phosphorylation |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] promotes the reaction [[ADRB1 protein binds to ADRB2 protein] which results in increased abundance of Cyclic AMP]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein] Colforsin results in increased expression of ADRB2 mRNA Colforsin results in increased phosphorylation of ADRB2 protein |
CTD |
PMID:14722251 PMID:19419905 PMID:24705868 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ADRB3 mRNA |
CTD |
PMID:10725275 |
|
NCBI chr16:69,003,541...69,006,632
Ensembl chr16:69,003,868...69,006,632
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects localization |
ISO |
[Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 mRNA; [Colforsin results in increased activity of AHR protein] which results in increased expression of CXCL8 protein; [Colforsin results in increased activity of AHR protein] which results in increased secretion of CXCL8 protein; Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]]; PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA] |
CTD |
PMID:15972329 PMID:17329248 PMID:17823304 PMID:23291558 |
|
NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
multiple interactions |
ISO |
AKAP13 protein modified form affects the reaction [Colforsin affects the localization of ADRA2C protein]; AKAP13 protein modified form affects the reaction [Colforsin results in increased expression of ADRA2C mRNA]; AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:24701590 |
|
NCBI chr 1:137,089,558...137,315,272
Ensembl chr 1:137,014,272...137,315,272
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
decreases expression |
ISO |
Colforsin results in decreased expression of AKR1C3 mRNA |
CTD |
PMID:28235592 |
|
NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein] |
CTD |
PMID:16339297 |
|
NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162
|
|
G |
Akt3 |
AKT serine/threonine kinase 3 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein] |
CTD |
PMID:16339297 |
|
NCBI chr13:95,076,308...95,348,913
Ensembl chr13:95,081,390...95,348,913
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of ALB protein] |
CTD |
PMID:27590029 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 9:94,197,616...94,201,910
Ensembl chr 9:94,197,618...94,201,084
|
|
G |
Alpp |
alkaline phosphatase, placental |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of ALPP mRNA [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of ALPP mRNA; Chlorpromazine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Clozapine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA]; Desipramine inhibits the reaction [Colforsin results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 9:94,189,961...94,193,054
Ensembl chr 9:94,190,067...94,192,813
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
increases activity |
EXP |
Colforsin results in increased activity of AOC1 protein |
CTD |
PMID:2860926 |
|
NCBI chr 4:78,496,043...78,515,582
Ensembl chr 4:78,496,043...78,515,584
|
|
G |
Appbp2 |
amyloid beta precursor protein binding protein 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of APPBP2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:72,503,347...72,545,141
Ensembl chr10:72,503,347...72,545,141
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK2 protein]; AR protein promotes the reaction [Colforsin results in increased expression of KLK3 protein]; Colforsin promotes the reaction [Metribolone results in increased activity of AR protein] Colforsin results in increased expression of AR protein |
CTD |
PMID:16751804 PMID:17219378 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Areg |
amphiregulin |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of AREG mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of AREG protein] |
CTD |
PMID:15284208 PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arntl |
aryl hydrocarbon receptor nuclear translocator-like |
increases expression |
ISO |
Colforsin results in increased expression of ARNTL mRNA |
CTD |
PMID:30524225 |
|
NCBI chr 1:178,039,002...178,137,469
Ensembl chr 1:178,039,063...178,137,465
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:164,502,099...164,573,947
Ensembl chr 1:164,502,389...164,593,139
|
|
G |
Atxn3 |
ataxin 3 |
decreases expression |
ISO |
Colforsin results in decreased expression of ATXN3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 6:125,817,420...125,853,461
Ensembl chr 6:125,819,640...125,853,461
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression |
ISO |
1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF mRNA]; 1-bromopropane inhibits the reaction [Colforsin results in increased expression of BDNF protein] Colforsin results in increased expression of BDNF mRNA; Colforsin results in increased expression of BDNF protein |
CTD |
PMID:19189864 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]; FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr17:26,955,142...27,112,820
Ensembl chr17:26,955,142...27,112,820
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1G protein] |
CTD |
PMID:17110049 |
|
NCBI chr10:82,129,071...82,197,828
Ensembl chr10:82,129,506...82,197,848
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1H protein] |
CTD |
PMID:17110049 |
|
NCBI chr10:14,730,932...14,789,201
Ensembl chr10:14,730,941...14,788,617
|
|
G |
Cacna1i |
calcium voltage-gated channel subunit alpha1 I |
multiple interactions |
EXP |
Mibefradil inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein]; Nickel inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CACNA1I protein] |
CTD |
PMID:17110049 |
|
NCBI chr 7:121,521,787...121,619,300
Ensembl chr 7:121,511,097...121,619,283
|
|
G |
Calcrl |
calcitonin receptor like receptor |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr 3:71,747,938...71,845,487
Ensembl chr 3:71,747,956...71,845,232
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
increases expression |
ISO |
Colforsin results in increased expression of CAMKK2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr12:39,253,409...39,302,601
Ensembl chr12:39,253,409...39,302,601
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
multiple interactions increases phosphorylation |
EXP |
Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CASK protein] |
CTD |
PMID:20067577 |
|
NCBI chr X:9,815,652...10,156,155
Ensembl chr X:9,815,652...10,156,155
|
|
G |
Casp1 |
caspase 1 |
increases activity |
EXP |
Colforsin results in increased activity of CASP1 mRNA; Colforsin results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
Colforsin results in increased activity of CASP3 protein Colforsin inhibits the reaction [Puromycin Aminonucleoside results in increased activity of CASP3 protein] KT 5720 inhibits the reaction [Colforsin results in increased activity of CASP3 protein] Colforsin inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:16396944 PMID:20131233 PMID:21745194 PMID:31278978 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:29283200 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
multiple interactions increases expression |
ISO |
3',4'-dimethoxy-alpha-naphthoflavone inhibits the reaction [Colforsin results in increased expression of CD55 mRNA] |
CTD |
PMID:22553215 |
|
NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
|
|
G |
Cdc6 |
cell division cycle 6 |
increases expression |
ISO |
Colforsin results in increased expression of CDC6 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdh1 |
cadherin 1 |
affects activity |
ISO |
Colforsin affects the activity of CDH1 protein |
CTD |
PMID:10413674 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions increases expression |
ISO EXP |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CEBPA mRNA] Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] Colforsin results in increased expression of CEBPA protein |
CTD |
PMID:17407152 PMID:21832167 |
|
NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of CEBPB mRNA [Atrazine co-treated with Colforsin] results in increased expression of CEBPB protein |
CTD |
PMID:14684744 PMID:25253736 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects localization increases activity multiple interactions |
ISO EXP |
Colforsin affects the localization of CFTR protein Colforsin results in increased activity of CFTR protein [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; AICA ribonucleotide inhibits the reaction [Colforsin results in increased activity of CFTR protein] [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein 3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; 5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; 6-hydroxy-10-chlorobenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein; [1-Methyl-3-isobutylxanthine co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [5-butyl-6-hydroxy-10-chlorobenzo(c)quinolizinium chloride co-treated with Colforsin] results in increased activity of CFTR protein mutant form; [[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of CFTR protein; [Colforsin co-treated with Genistein] results in increased activity of CFTR protein; [Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [Colforsin co-treated with NS 004] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin co-treated with lumacaftor] results in increased activity of CFTR protein mutant form; [ivacaftor co-treated with Colforsin] results in increased activity of CFTR protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Brefeldin A inhibits the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]; Colforsin binds to and results in decreased activity of CFTR protein; Colforsin promotes the reaction [CFTR protein affects the export of Chlorides]; Colforsin results in increased phosphorylation of and results in increased activity of CFTR protein; fenamic acid inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; fenamic acid inhibits the reaction [Colforsin results in increased activity of CFTR protein]; geldanamycin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; geldanamycin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Glyburide inhibits the reaction [[[Colforsin co-treated with Genistein] results in increased activity of CFTR protein] which results in increased transport of Iodides]; Glyburide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of CFTR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CFTR protein]; Ozone inhibits the reaction [Colforsin results in increased activity of CFTR protein]; Thapsigargin promotes the reaction [5-butyl-7-chloro-6-hydroxybenzo(c)quinolizinium inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; Thapsigargin promotes the reaction [miglustat inhibits the reaction [CFTR protein mutant form inhibits the reaction [[Colforsin co-treated with Genistein] results in increased transport of Iodides]]]; VRT 532 analog promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form]; VRT 532 promotes the reaction [Colforsin results in increased activity of CFTR protein mutant form] Colforsin analog results in increased activity of CFTR protein mutant form; Colforsin results in increased activity of CFTR protein; Colforsin results in increased activity of CFTR protein mutant form |
CTD |
PMID:12519745 PMID:12914781 PMID:14502435 PMID:14967738 PMID:15163550 PMID:15194485 PMID:15246976 PMID:15389550 PMID:15517342 PMID:15763242 PMID:15790911 PMID:15986093 PMID:15994425 PMID:16027156 PMID:16038730 PMID:17596272 PMID:18230692 PMID:19061877 PMID:21724857 PMID:22074181 PMID:32374624 |
|
NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
increases secretion increases expression multiple interactions |
ISO EXP |
Colforsin results in increased secretion of CGA protein Colforsin results in increased expression of CGA mRNA Colforsin promotes the reaction [CGA protein results in increased abundance of Cyclic AMP] Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] |
CTD |
PMID:8404651 PMID:16503475 PMID:20378682 |
|
NCBI chr 5:50,362,491...50,393,368
Ensembl chr 5:50,381,244...50,393,367
|
|
G |
Cidec |
cell death-inducing DFFA-like effector c |
increases expression |
ISO |
Colforsin results in increased expression of CIDEC protein |
CTD |
PMID:21097823 |
|
NCBI chr 4:145,377,482...145,390,497
Ensembl chr 4:145,377,431...145,390,497
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions affects response to substance increases activity |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR1 mRNA; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR1 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]]; delta(9)-tetrahydrocannabinolic acid inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR1 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR1 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR1 protein affects the susceptibility to Colforsin |
CTD |
PMID:27429655 PMID:27527584 PMID:28861508 PMID:31154070 |
|
NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions increases activity affects response to substance |
ISO |
(1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; (4-ethyl-1-naphthalenyl)(1-(5-fluoropentyl)-1H-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyfluoro-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 1-pentyl-3-(1-naphthoyl)indole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-((adamantan-1-yl)carbonyl)-1-pentylindole inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Dronabinol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of CNR2 mRNA; [virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; AM 6527 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; AM 6527 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; CNR2 protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; Dronabinol inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Dronabinol inhibits the reaction [Colforsin results in increased activity of CNR2 protein]; FDU-PB-22 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; FUB-PB-22 compound inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indazoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Indoles analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(1-adamantyl)-1-pentylindazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; SR 144528 inhibits the reaction [[virodhamine binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; THJ-2201 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 analog inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]]; XLR-11 inhibits the reaction [[3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol binds to and results in increased activity of CNR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]] CNR2 protein affects the susceptibility to Colforsin |
CTD |
PMID:17558435 PMID:27429655 PMID:27527584 PMID:28861508 PMID:30504240 PMID:31154070 |
|
NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases activity increases expression increases phosphorylation multiple interactions |
ISO EXP |
Colforsin results in increased activity of CREB1 protein Colforsin results in increased expression of CREB1 protein modified form Colforsin results in increased phosphorylation of CREB1 protein 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; Colforsin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CREB1 protein modified form]; Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Okadaic Acid inhibits the reaction [resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]]; resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 mutant form inhibits the reaction [resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] AKAP13 protein modified form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; Colforsin results in increased phosphorylation of and results in increased activity of CREB1 protein oxophenylarsine inhibits the reaction [Colforsin results in increased activity of CREB1 protein]; oxophenylarsine inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:10908723 PMID:15522277 PMID:17141199 PMID:17322281 PMID:17460731 PMID:17680988 PMID:18004999 PMID:20512473 PMID:21745194 PMID:23292070 PMID:24701590 PMID:27509375 PMID:27590029 PMID:28601556 PMID:29179997 PMID:30610963 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein] |
CTD |
PMID:16166624 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crem |
cAMP responsive element modulator |
increases expression |
EXP |
Colforsin results in increased expression of CREM mRNA; Colforsin results in increased expression of CREM mRNA alternative form; Colforsin results in increased expression of CREM protein |
CTD |
PMID:8810303 PMID:12791704 |
|
NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [Colforsin results in increased chemical synthesis of Testosterone] |
CTD |
PMID:2153673 |
|
NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863
|
|
G |
Crls1 |
cardiolipin synthase 1 |
increases expression |
ISO |
Colforsin results in increased expression of CRLS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 3:125,503,638...125,522,460
Ensembl chr 3:125,503,638...125,522,441
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
EXP |
Colforsin inhibits the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:8769853 |
|
NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression multiple interactions increases expression |
ISO EXP |
Colforsin affects the expression of CYP11A1 mRNA [Colforsin co-treated with Zearalenone] results in increased expression of CYP11A1 mRNA Colforsin results in increased expression of CYP11A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP11A1 mRNA; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of CYP11A1 mRNA] [Atrazine co-treated with Colforsin] results in increased expression of CYP11A1 mRNA; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein] |
CTD |
PMID:14691014 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22446829 PMID:22948218 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26783879 PMID:28235592 PMID:31557376 |
|
NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
|
|
G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
increases expression multiple interactions increases activity |
ISO |
Colforsin results in increased expression of CYP11B1 mRNA [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B1 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B1 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B1 mRNA] Colforsin results in increased activity of CYP11B1 protein |
CTD |
PMID:12525251 PMID:17080404 PMID:19164467 PMID:19900470 PMID:21256172 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 |
|
NCBI chr 7:116,248,759...116,255,205
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
increases expression multiple interactions increases activity |
ISO |
Colforsin results in increased expression of CYP11B2 mRNA 1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein]; 2,2-(2-chlorophenyl-4'-chlorophenyl)-1,1-dichloroethene inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein]; Etomidate inhibits the reaction [Colforsin results in increased activity of CYP11B1 protein] [1-chloro-4-(2,2-dichloro-1-(4-chlorophenyl)ethenyl)-3-(methylsulfonyl)benzene co-treated with Colforsin] affects the expression of CYP11B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of CYP11B2 mRNA; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP11B2 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of CYP11B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:18651133 PMID:19164467 PMID:19900470 PMID:21256172 PMID:22446829 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31557376 |
|
NCBI chr 7:116,155,928...116,161,781
Ensembl chr 7:116,156,219...116,255,167
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of CYP17A1 mRNA [Colforsin co-treated with triptolide] results in decreased expression of CYP17A1 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Ketoconazole inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Metyrapone inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:15625562 PMID:15886251 PMID:16935330 PMID:17080404 PMID:20726872 PMID:22446829 PMID:22461451 PMID:23370353 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 |
|
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions |
ISO EXP |
Colforsin results in increased activity of CYP19A1 protein Colforsin results in increased expression of CYP19A1 mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; [Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Estradiol; [Colforsin results in increased activity of CYP19A1 protein] which results in increased abundance of Testosterone; Alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Atrazine inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; BMP6 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased activity of CYP19A1 protein]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; ZNF461 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] |
CTD |
PMID:14691014 PMID:16357189 PMID:16935330 PMID:16996190 PMID:17080404 PMID:18936084 PMID:19822197 PMID:20087668 PMID:20723554 PMID:20726872 PMID:22446829 PMID:22461451 PMID:22948218 PMID:24361490 PMID:25765474 PMID:25871633 PMID:28235592 PMID:28859905 PMID:29701941 PMID:31100596 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions affects expression |
EXP ISO |
Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein] Valproic Acid affects the reaction [Colforsin affects the expression of CYP1A1 mRNA] Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:1849469 PMID:15710352 PMID:20726872 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO EXP |
Colforsin affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] Colforsin inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein] |
CTD |
PMID:1849469 PMID:15710352 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression |
EXP |
Colforsin results in increased expression of CYP1B1 mRNA; Colforsin results in increased expression of CYP1B1 protein |
CTD |
PMID:7588239 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
Colforsin results in increased expression of CYP2A5 mRNA |
CTD |
PMID:11162586 |
|
NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
|
|
G |
Dbh |
dopamine beta-hydroxylase |
multiple interactions increases expression |
EXP |
Colforsin inhibits the reaction [Atrazine results in decreased expression of DBH protein]; Colforsin inhibits the reaction [Simazine results in decreased expression of DBH protein] Colforsin results in increased expression of DBH protein |
CTD |
PMID:14550852 |
|
NCBI chr 3:5,709,236...5,731,895
Ensembl chr 3:5,709,236...5,731,898
|
|
G |
Dct |
dopachrome tautomerase |
increases expression |
ISO |
Colforsin results in increased expression of DCT mRNA; Colforsin results in increased expression of DCT protein |
CTD |
PMID:17460731 PMID:28601556 |
|
NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
increases activity multiple interactions increases expression |
ISO EXP |
Colforsin results in increased activity of DIO2 protein Buthionine Sulfoximine inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]; Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]; Sodium Selenite inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased activity of DIO2 protein]]; U 0126 inhibits the reaction [Hydrogen Peroxide inhibits the reaction [Colforsin results in increased expression of DIO2 mRNA]] |
CTD |
PMID:18420745 PMID:19036883 |
|
NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
multiple interactions |
EXP |
Colforsin promotes the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] |
CTD |
PMID:18420745 |
|
NCBI chr 6:134,627,278...134,629,139
Ensembl chr 6:134,627,278...134,629,138
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions decreases expression |
ISO |
PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr11:88,830,968...88,882,271
Ensembl chr11:88,830,957...88,880,198
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; epigallocatechin gallate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17958328 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Dynll2 |
dynein light chain LC8-type 2 |
increases expression |
ISO |
Colforsin results in increased expression of DYNLL2 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr10:75,262,536...75,281,302
Ensembl chr10:75,262,537...75,270,561
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of CALCRL mRNA]; Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] |
CTD |
PMID:32092105 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egr1 |
early growth response 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of EGR1 mRNA; Colforsin results in decreased expression of EGR1 protein Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 mRNA]; Colforsin inhibits the reaction [Ethanol results in increased expression of EGR1 protein]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 mRNA]; Ethanol inhibits the reaction [Colforsin results in decreased expression of EGR1 protein] |
CTD |
PMID:29802914 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Eif2b5 |
eukaryotic translation initiation factor 2B subunit epsilon |
increases expression |
ISO |
Colforsin results in increased expression of EIF2B5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:84,080,273...84,090,259
Ensembl chr11:84,080,273...84,090,259
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects expression multiple interactions |
ISO |
Colforsin affects the expression of EPHX1 mRNA Valproic Acid affects the reaction [Colforsin affects the expression of EPHX1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Eps8 |
epidermal growth factor receptor pathway substrate 8 |
decreases expression |
ISO |
Colforsin results in decreased expression of EPS8 mRNA |
CTD |
PMID:15313392 PMID:15967414 |
|
NCBI chr 4:171,475,155...171,645,620
Ensembl chr 4:171,475,567...171,591,882
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
Colforsin results in increased expression of EREG mRNA |
CTD |
PMID:15313392 PMID:15474502 PMID:15967414 PMID:20378682 |
|
NCBI chr14:18,577,620...18,591,395
Ensembl chr14:18,576,355...18,591,394
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
multiple interactions increases expression increases secretion |
ISO |
Colforsin promotes the reaction [Benzo(a)pyrene results in increased expression of ERVFRD-1 mRNA] Colforsin results in increased expression of ERVFRD-1 mRNA; Colforsin results in increased expression of ERVFRD-1 protein Colforsin results in increased secretion of ERVFRD-1 protein |
CTD |
PMID:24361490 PMID:29679653 PMID:31278978 |
|
NCBI chr12:25,161,130...25,168,182
Ensembl chr12:25,161,130...25,168,182
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of ESR1 mRNA |
CTD |
PMID:31278978 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO |
Colforsin inhibits the reaction [ESR2 gene mutant form inhibits the reaction [CGA protein results in increased abundance of Cyclic AMP]] Colforsin results in decreased expression of ESR2 mRNA |
CTD |
PMID:20378682 PMID:31278978 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Esrra |
estrogen related receptor, alpha |
increases expression |
ISO |
Colforsin results in increased expression of ESRRA mRNA; Colforsin results in increased expression of ESRRA protein |
CTD |
PMID:20351196 |
|
NCBI chr 1:222,168,729...222,178,842
Ensembl chr 1:222,168,730...222,178,725
|
|
G |
Evi5 |
ecotropic viral integration site 5 |
increases expression |
ISO |
Colforsin results in increased expression of EVI5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr14:2,892,738...3,038,237
Ensembl chr14:2,892,753...3,038,237
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
ISO |
Colforsin inhibits the reaction [F2 protein results in increased uptake of Manganese] |
CTD |
PMID:2125206 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
[C186 65 binds to and results in increased activity of F2R protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr 2:26,118,760...26,135,340
Ensembl chr 2:26,118,760...26,135,340
|
|
G |
F2rl3 |
F2R like thrombin or trypsin receptor 3 |
multiple interactions |
ISO |
[GYPGKF-NH(2) binds to and results in increased activity of F2RL3 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22207716 |
|
NCBI chr16:18,817,797...18,819,790
Ensembl chr16:18,814,622...18,819,833
|
|
G |
Fads1 |
fatty acid desaturase 1 |
increases expression |
ISO |
Colforsin results in increased expression of FADS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:226,234,034...226,249,118
Ensembl chr 1:226,234,074...226,249,138
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
[Colforsin co-treated with 6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime] results in increased expression of FASN mRNA; [Colforsin co-treated with Leflunomide] results in increased expression of FASN mRNA; [Colforsin co-treated with teriflunomide] results in increased expression of FASN mRNA |
CTD |
PMID:30364229 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Fgf10 |
fibroblast growth factor 10 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12533312 PMID:14975937 |
|
NCBI chr 2:51,673,480...51,747,533
Ensembl chr 2:51,672,722...51,750,369
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGF2 mRNA; Colforsin results in increased expression of FGF2 protein |
CTD |
PMID:10320526 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
EXP |
Colforsin results in decreased expression of FGF5 mRNA |
CTD |
PMID:11598998 |
|
NCBI chr14:12,974,921...12,996,046
Ensembl chr14:12,974,921...12,995,584
|
|
G |
Fgf8 |
fibroblast growth factor 8 |
increases activity |
ISO |
Colforsin results in increased activity of FGF8 protein |
CTD |
PMID:15193767 |
|
NCBI chr 1:265,492,949...265,498,965
Ensembl chr 1:265,493,124...265,498,831
|
|
G |
Fgf9 |
fibroblast growth factor 9 |
multiple interactions |
ISO |
FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]] |
CTD |
PMID:22798350 |
|
NCBI chr15:38,341,657...38,386,945
Ensembl chr15:38,341,089...38,387,316
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR1 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr16:71,265,390...71,319,046
Ensembl chr16:71,266,248...71,319,449
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
increases expression |
ISO |
Colforsin results in increased expression of FGFR2 mRNA |
CTD |
PMID:10320526 |
|
NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
Colforsin promotes the reaction [Dexamethasone results in increased expression of FKBP5 mRNA] |
CTD |
PMID:19255438 |
|
NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
Colforsin results in increased expression of FOSB mRNA; Colforsin results in increased expression of FOSB protein |
CTD |
PMID:17324382 |
|
NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
EXP |
Colforsin results in increased expression of FSHB mRNA; Colforsin results in increased expression of FSHB protein |
CTD |
PMID:8404651 |
|
NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
|
|
G |
Fst |
follistatin |
multiple interactions |
ISO |
FST protein inhibits the reaction [BMP6 protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]] |
CTD |
PMID:18936084 |
|
NCBI chr 2:46,537,589...46,544,813
Ensembl chr 2:46,538,700...46,544,457
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP ISO |
[Dexamethasone co-treated with Colforsin] results in increased expression of G6PC1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of G6PC1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of G6PC1 mRNA] |
CTD |
PMID:18972406 PMID:30364229 |
|
NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
increases expression |
EXP |
Colforsin results in increased expression of GABRA1 |
CTD |
PMID:9147380 |
|
NCBI chr10:27,310,718...27,371,802
Ensembl chr10:27,310,725...27,366,665
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
decreases expression |
EXP |
Colforsin results in decreased expression of GABRA6 |
CTD |
PMID:9147380 |
|
NCBI chr10:27,847,447...27,862,896
Ensembl chr10:27,847,439...27,862,868
|
|
G |
Gas6 |
growth arrest specific 6 |
decreases expression |
ISO |
Colforsin results in decreased expression of GAS6 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr16:81,213,364...81,243,824
Ensembl chr16:81,213,364...81,243,757
|
|
G |
Gast |
gastrin |
multiple interactions increases secretion |
ISO EXP |
Calcium promotes the reaction [Colforsin results in increased secretion of GAST protein]; Nitrendipine inhibits the reaction [Colforsin results in increased secretion of GAST protein] 2',5'-dideoxyadenosine inhibits the reaction [Colforsin results in increased secretion of GAST protein] |
CTD |
PMID:9277405 PMID:19208342 |
|
NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
|
|
G |
Gcg |
glucagon |
multiple interactions increases secretion |
EXP |
Colforsin promotes the reaction [Pyruvic Acid results in increased secretion of GCG protein] Colforsin results in increased secretion of GCG protein |
CTD |
PMID:15919803 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Gcm1 |
glial cells missing transcription factor 1 |
multiple interactions decreases expression |
ISO |
Colforsin promotes the reaction [GCM1 protein binds to CREBBP protein]; Colforsin results in increased acetylation of and results in increased activity of GCM1 protein; CREBBP protein affects the reaction [Colforsin results in increased activity of GCM1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased activity of GCM1 protein]; trichostatin A promotes the reaction [Colforsin results in increased acetylation of and results in increased activity of GCM1 protein] Colforsin results in decreased expression of GCM1 mRNA |
CTD |
PMID:16166624 PMID:31278978 |
|
NCBI chr 8:85,355,766...85,369,002
Ensembl chr 8:85,355,766...85,369,002
|
|
G |
Gh1 |
growth hormone 1 |
increases secretion multiple interactions |
ISO EXP |
Colforsin results in increased secretion of GH1 protein GH1 protein promotes the reaction [Colforsin results in increased metabolism of Lipids] |
CTD |
PMID:14981226 PMID:19952226 |
|
NCBI chr10:94,486,204...94,488,181
Ensembl chr10:94,486,205...94,488,180
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of GLI2 mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr13:34,829,021...35,049,172
Ensembl chr13:34,829,139...35,048,444
|
|
G |
Gnai3 |
G protein subunit alpha i3 |
increases expression |
ISO |
Colforsin results in increased expression of GNAI3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:210,896,779...210,934,733
Ensembl chr 2:210,896,656...210,934,749
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions |
ISO |
[Colforsin binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Colforsin binds to and results in increased activity of GPBAR1 protein |
CTD |
PMID:17963371 |
|
NCBI chr 9:81,555,914...81,560,931
Ensembl chr 9:81,559,605...81,560,594
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases phosphorylation multiple interactions |
EXP |
Colforsin results in increased phosphorylation of GRIN1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of GRIN1 protein] |
CTD |
PMID:14622123 |
|
NCBI chr 3:2,507,745...2,534,664
Ensembl chr 3:2,506,896...2,534,663
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions increases expression |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of GRIN2B protein] Colforsin results in increased expression of GRIN2B mRNA; Colforsin results in increased expression of GRIN2B protein |
CTD |
PMID:20067577 |
|
NCBI chr 4:169,541,620...170,000,216
Ensembl chr 4:169,560,387...169,999,873
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Colforsin results in increased phosphorylation of and results in decreased activity of GSK3B protein |
CTD |
PMID:15950778 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
affects expression multiple interactions |
ISO |
Colforsin affects the expression of HAMP mRNA Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA] |
CTD |
PMID:25633564 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hcar2 |
hydroxycarboxylic acid receptor 2 |
multiple interactions |
ISO |
[3-Hydroxybutyric Acid results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Niacin results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Pertussis Toxin inhibits the reaction [[Nicotinic Acids binds to and results in increased activity of HCAR2 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:17124637 PMID:19223991 |
|
NCBI chr12:38,160,464...38,161,546
Ensembl chr12:38,160,464...38,161,546
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression increases expression multiple interactions |
ISO |
Colforsin affects the expression of HMGCR mRNA Colforsin results in increased expression of HMGCR mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HMGCR mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HMGCR mRNA; AR protein promotes the reaction [Colforsin results in increased expression of HMGCR protein]; Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HMGCR mRNA] |
CTD |
PMID:16751804 PMID:16935330 PMID:20726872 PMID:30825513 PMID:31557376 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Colforsin results in increased expression of HMOX1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of HMOX1 protein] Colforsin results in increased expression of HMOX1 mRNA; Colforsin results in increased expression of HMOX1 protein |
CTD |
PMID:15179140 PMID:16439612 PMID:19483313 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
multiple interactions |
EXP |
HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 7:144,865,302...144,871,592
Ensembl chr 7:144,865,608...144,871,585
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
EXP |
Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr17:6,664,730...6,676,753
Ensembl chr17:6,665,659...6,676,654
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
ISO |
Dimaprit inhibits the reaction [HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HRH2 protein promotes the reaction [Colforsin results in increased abundance of Cyclic AMP] |
CTD |
PMID:9187264 |
|
NCBI chr17:10,912,959...10,931,389
Ensembl chr17:10,921,507...10,952,441
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions |
EXP |
[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; ciproxifan inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; Pertussis Toxin inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:21276809 |
|
NCBI chr 3:175,474,310...175,479,395
Ensembl chr 3:175,473,078...175,479,395
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [1,7-dimethylxanthine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein]; Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 mRNA]; Colforsin inhibits the reaction [Ethanol results in decreased expression of HSD11B2 protein]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 mRNA]; Ethanol inhibits the reaction [Colforsin results in increased expression of HSD11B2 protein] Colforsin results in increased expression of HSD11B2 mRNA; Colforsin results in increased expression of HSD11B2 protein |
CTD |
PMID:22701600 PMID:24361490 PMID:29802914 |
|
NCBI chr19:37,476,083...37,481,326
Ensembl chr19:37,476,095...37,481,307
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
affects expression increases expression multiple interactions |
ISO |
Colforsin affects the expression of HSD17B1 mRNA Colforsin results in increased expression of HSD17B1 mRNA [Colforsin co-treated with Aminoglutethimide] results in decreased expression of HSD17B1 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD17B1 mRNA; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B1 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:22446829 |
|
NCBI chr10:88,987,558...88,989,758
Ensembl chr10:88,987,558...88,989,757
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
increases expression |
ISO |
Colforsin results in increased expression of HSD17B3 mRNA |
CTD |
PMID:22461451 |
|
NCBI chr17:1,579,319...1,610,745
Ensembl chr17:1,579,319...1,610,745
|
|
G |
Hsd17b4 |
hydroxysteroid (17-beta) dehydrogenase 4 |
affects expression multiple interactions increases expression |
ISO |
Colforsin affects the expression of HSD17B4 mRNA Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Ketoconazole promotes the reaction [Colforsin results in increased expression of HSD17B4 mRNA]; Valproic Acid affects the reaction [Colforsin affects the expression of HSD17B4 mRNA] |
CTD |
PMID:16935330 PMID:20726872 PMID:22446829 |
|
NCBI chr18:44,810,462...44,897,677
Ensembl chr18:44,810,388...44,897,640
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of HSD3B1 mRNA] |
CTD |
PMID:18936084 |
|
|
|
G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of HSD3B2 mRNA [Colforsin co-treated with Ketoconazole] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with Metyrapone] results in decreased expression of HSD3B2 mRNA; [Colforsin co-treated with triptolide] results in decreased expression of HSD3B2 mRNA; Apigenin inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; daidzein inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of HSD3B2 mRNA] |
CTD |
PMID:16935330 PMID:17080404 PMID:20726872 PMID:21256172 PMID:22446829 PMID:23370353 PMID:25765474 PMID:25871633 PMID:28235592 PMID:31100596 PMID:31557376 |
|
NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases response to substance |
ISO |
HSPA5 protein results in increased susceptibility to Colforsin |
CTD |
PMID:22912664 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of HSPD1 mRNA] |
CTD |
PMID:32092105 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
[JB-788 binds to and results in increased activity of HTR1A protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]]; HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Melitten inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 PMID:20580787 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
multiple interactions |
ISO |
HTR1B affects the reaction [almotriptan inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11134654 |
|
NCBI chr 8:89,113,984...89,130,830
Ensembl chr 8:89,129,453...89,130,991
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
EXP |
Colforsin inhibits the reaction [N-(piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno(1,2-c)pyrazole-3-carboxamide results in increased expression of HTR2A mRNA] |
CTD |
PMID:22791651 |
|
NCBI chr15:56,666,152...56,732,469
Ensembl chr15:56,666,012...56,735,382
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
[Bromocriptine binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Lisuride binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Metergoline binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Methiothepin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP] |
CTD |
PMID:19509219 |
|
NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
|
|
G |
Iapp |
islet amyloid polypeptide |
increases expression |
EXP |
Colforsin results in increased expression of IAPP mRNA |
CTD |
PMID:9142872 |
|
NCBI chr 4:176,509,863...176,517,903
Ensembl chr 4:176,510,696...176,516,083
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Reactive Oxygen Species results in increased expression of ICAM1 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] |
CTD |
PMID:10495789 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [EDN1 protein results in increased expression of ICAM2 mRNA] |
CTD |
PMID:25194819 |
|
NCBI chr10:94,569,889...94,581,218
Ensembl chr10:94,569,890...94,576,512
|
|
G |
Ier3 |
immediate early response 3 |
affects response to substance |
ISO |
IER3 protein affects the susceptibility to Colforsin |
CTD |
PMID:20713914 |
|
NCBI chr20:3,438,798...3,440,002
Ensembl chr20:3,438,798...3,440,769
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Colforsin inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone] |
CTD |
PMID:22798350 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of IGFBP1 [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:12093828 PMID:31154070 |
|
NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IKBKB mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr16:74,177,233...74,230,809
Ensembl chr16:74,177,215...74,230,815
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
Colforsin results in decreased expression of IL10 protein |
CTD |
PMID:10996031 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il11 |
interleukin 11 |
increases expression |
ISO |
Colforsin results in increased expression of IL11 mRNA |
CTD |
PMID:22138297 |
|
NCBI chr 1:72,636,959...72,643,255
Ensembl chr 1:72,635,267...72,643,255
|
|
G |
Il12a |
interleukin 12A |
decreases expression |
ISO |
Colforsin results in decreased expression of IL12A protein |
CTD |
PMID:10996031 |
|
NCBI chr 2:165,076,945...165,083,996
Ensembl chr 2:165,076,607...165,084,318
|
|
G |
Il12b |
interleukin 12B |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [oxophenylarsine promotes the reaction [Lipopolysaccharides results in increased expression of IL12B protein]]; Colforsin results in increased expression of [IL12B protein binds to IL23A protein] Colforsin results in increased expression of IL12B protein |
CTD |
PMID:10996031 PMID:15180965 PMID:20512473 |
|
NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
|
|
G |
Il13 |
interleukin 13 |
decreases secretion decreases expression |
ISO |
Colforsin results in decreased secretion of IL13 protein Colforsin results in decreased expression of IL13 mRNA |
CTD |
PMID:16083514 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein] |
CTD |
PMID:11112151 PMID:27590029 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of IL23A protein Colforsin results in increased expression of [IL12B protein binds to IL23A protein] |
CTD |
PMID:15180965 |
|
NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Colforsin results in decreased expression of IL2RA protein |
CTD |
PMID:1709825 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Colforsin inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Colforsin inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] |
CTD |
PMID:11886533 |
|
NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
EXP ISO |
Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Colforsin inhibits the reaction [IL6 protein results in increased expression of HAMP mRNA]; Colforsin promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin results in increased secretion of IL6 protein oxophenylarsine inhibits the reaction [Colforsin results in increased secretion of IL6 protein] |
CTD |
PMID:17141199 PMID:20388727 PMID:21803157 PMID:24771768 PMID:25633564 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
ISO |
FST protein inhibits the reaction [INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone]]; INHBA protein inhibits the reaction [Colforsin results in increased secretion of Progesterone] |
CTD |
PMID:18936084 |
|
NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
|
|
G |
Insig1 |
insulin induced gene 1 |
multiple interactions increases expression |
ISO |
AR protein promotes the reaction [Colforsin results in increased expression of INSIG1 protein] Colforsin results in increased expression of INSIG1 mRNA; Colforsin results in increased expression of INSIG1 protein |
CTD |
PMID:16751804 |
|
NCBI chr 4:342,302...350,515
Ensembl chr 4:342,302...350,515
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IRS1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 9:88,033,668...88,086,488
Ensembl chr 9:88,033,668...88,086,488
|
|
G |
Itga1 |
integrin subunit alpha 1 |
affects response to substance |
EXP |
ITGA1 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr 2:47,127,403...47,281,387
Ensembl chr 2:47,127,219...47,281,421
|
|
G |
Itga3 |
integrin subunit alpha 3 |
affects response to substance |
EXP |
ITGA3 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr10:82,855,841...82,887,755
Ensembl chr10:82,855,613...82,887,497
|
|
G |
Itgb1 |
integrin subunit beta 1 |
affects response to substance |
EXP |
ITGB1 protein affects the susceptibility to Colforsin |
CTD |
PMID:15836982 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Itgb5 |
integrin subunit beta 5 |
increases expression |
ISO |
Colforsin results in increased expression of ITGB5 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr11:70,056,500...70,172,164
Ensembl chr11:70,056,500...70,172,372
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of [ADRB1 protein binds to ADRB2 protein]] affects the reaction [KCNH2 protein results in increased transport of Potassium] |
CTD |
PMID:19419905 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Lep |
leptin |
decreases expression decreases secretion multiple interactions |
ISO |
Colforsin results in decreased expression of LEP mRNA Colforsin results in decreased secretion of LEP protein Colforsin inhibits the reaction [Caffeine results in decreased expression of LEP mRNA] |
CTD |
PMID:9002984 PMID:26367767 PMID:27381457 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lhb |
luteinizing hormone subunit beta |
increases expression multiple interactions |
EXP |
Colforsin results in increased expression of LHB protein [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP; [Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; CRH protein inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Cyclic AMP]; Tetradecanoylphorbol Acetate inhibits the reaction [[Colforsin co-treated with CGB3 protein] results in increased chemical synthesis of Testosterone] |
CTD |
PMID:2153673 PMID:8404651 |
|
NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
|
|
G |
Lhcgr |
luteinizing hormone/choriogonadotropin receptor |
multiple interactions |
ISO |
[Colforsin co-treated with deoxynivalenol] results in increased expression of LHCGR mRNA; [Colforsin co-treated with Zearalenone] results in increased expression of LHCGR mRNA |
CTD |
PMID:26783879 |
|
NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
|
|
G |
Lipe |
lipase E, hormone sensitive type |
affects localization |
EXP |
Colforsin affects the localization of LIPE protein |
CTD |
PMID:11160373 |
|
NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
Colforsin results in increased expression of LPL mRNA |
CTD |
PMID:9032464 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Ltbp2 |
latent transforming growth factor beta binding protein 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of LTBP2 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr 6:108,500,114...108,596,653
Ensembl chr 6:108,500,112...108,596,569
|
|
G |
Ltc4s |
leukotriene C4 synthase |
decreases secretion |
ISO |
Colforsin results in decreased secretion of LTC4S protein |
CTD |
PMID:16083514 |
|
NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions decreases secretion increases secretion |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Colforsin results in increased secretion of LYZ protein]; [Thapsigargin co-treated with Colforsin] results in increased secretion of LYZ protein Colforsin results in decreased secretion of LYZ protein |
CTD |
PMID:15194485 PMID:15234967 |
|
NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
|
|
G |
Maf |
MAF bZIP transcription factor |
decreases expression |
ISO |
Colforsin results in decreased expression of MAF mRNA |
CTD |
PMID:16751804 |
|
NCBI chr19:48,179,826...48,200,995
Ensembl chr19:48,194,804...48,196,748
|
|
G |
Map7 |
microtubule-associated protein 7 |
increases expression |
ISO |
Colforsin results in increased expression of MAP7 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:15,620,665...15,748,203
Ensembl chr 1:15,620,653...15,748,203
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK1 protein] 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]; Colforsin promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK1 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK1 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [Colforsin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11093795 PMID:11675405 PMID:12533312 PMID:14975937 PMID:15385614 PMID:17322281 PMID:18004999 PMID:20378682 PMID:21177760 PMID:22875961 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation increases activity multiple interactions |
ISO EXP |
Colforsin results in increased phosphorylation of MAPK3 protein Colforsin results in increased activity of MAPK3 protein 1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; Colforsin inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]; Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [1-Methyl-3-isobutylxanthine inhibits the reaction [Testosterone results in increased phosphorylation of MAPK3 protein]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased phosphorylation of MAPK3 protein]; Propranolol inhibits the reaction [Colforsin results in increased activity of MAPK3 protein] Colforsin inhibits the reaction [FGF10 protein results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased activity of MAPK3 protein] |
CTD |
PMID:11093795 PMID:11675405 PMID:12533312 PMID:14975937 PMID:15385614 PMID:17322281 PMID:18004999 PMID:20378682 PMID:21177760 PMID:22875961 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mc2r |
melanocortin 2 receptor |
multiple interactions increases expression |
ISO |
Valproic Acid inhibits the reaction [Colforsin results in increased expression of MC2R mRNA] |
CTD |
PMID:20726872 PMID:25765474 |
|
NCBI chr18:64,166,959...64,178,729
Ensembl chr18:64,167,191...64,177,729
|
|
G |
Med28 |
mediator complex subunit 28 |
increases expression |
ISO |
Colforsin results in increased expression of MED28 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr14:70,089,225...70,098,021
Ensembl chr14:70,089,225...70,098,021
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 8:73,030,047...73,030,131
Ensembl chr 8:73,030,047...73,030,131
|
|
G |
Mitf |
melanocyte inducing transcription factor |
increases expression |
ISO |
Colforsin results in increased expression of MITF mRNA; Colforsin results in increased expression of MITF protein |
CTD |
PMID:17460731 PMID:28601556 |
|
NCBI chr 4:130,172,484...130,425,496
Ensembl chr 4:130,172,727...130,425,532
|
|
G |
Mmp16 |
matrix metallopeptidase 16 |
increases expression |
ISO |
Colforsin results in increased expression of MMP16 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:31,568,344...31,818,368
Ensembl chr 5:31,568,419...31,810,484
|
|
G |
Mterf4 |
mitochondrial transcription termination factor 4 |
decreases expression |
ISO |
Colforsin results in decreased expression of MTERF4 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 9:100,440,482...100,445,158
Ensembl chr 9:100,440,486...100,445,158
|
|
G |
Muc4 |
mucin 4, cell surface associated |
increases expression |
ISO |
Colforsin results in increased expression of MUC4 protein |
CTD |
PMID:28049186 |
|
NCBI chr11:71,242,973...71,285,217
Ensembl chr11:71,243,334...71,284,939
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Dinoprostone results in increased expression of MYH7 protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of MYH7 mRNA] |
CTD |
PMID:18851973 |
|
NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
|
|
G |
Nav1 |
neuron navigator 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of NAV1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr13:52,260,474...52,515,016
Ensembl chr13:52,267,254...52,514,875
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKB1 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
|
|
G |
Ngf |
nerve growth factor |
multiple interactions increases expression |
EXP |
[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of NGF mRNA Colforsin results in increased expression of NGF mRNA |
CTD |
PMID:2174743 PMID:2853697 |
|
NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
|
|
G |
Ngly1 |
N-glycanase 1 |
increases expression |
ISO |
Colforsin results in increased expression of NGLY1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr15:10,405,453...10,455,973
Ensembl chr15:10,405,164...10,455,956
|
|
G |
Nmu |
neuromedin U |
increases expression |
EXP |
Colforsin results in increased expression of NMU mRNA |
CTD |
PMID:23423171 |
|
NCBI chr14:34,353,683...34,381,968
Ensembl chr14:34,354,503...34,381,828
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Dinoprostone results in increased expression of NPPA protein]; Colforsin inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:11470465 PMID:18851973 |
|
NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
|
|
G |
Nr0b1 |
nuclear receptor subfamily 0, group B, member 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of NR0B1 mRNA Valproic Acid inhibits the reaction [Colforsin results in decreased expression of NR0B1 mRNA] |
CTD |
PMID:20726872 |
|
NCBI chr X:54,734,385...54,738,513
Ensembl chr X:54,734,385...54,738,513
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity decreases expression |
EXP ISO |
Colforsin results in increased activity of NR1I2 protein Colforsin results in decreased expression of NR1I2 mRNA |
CTD |
PMID:27732639 PMID:29933105 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
increases activity |
ISO |
Colforsin results in increased activity of NR3C1 protein |
CTD |
PMID:19255438 |
|
NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of NR4A1 mRNA; Colforsin results in increased expression of NR4A1 protein [Colforsin co-treated with deoxynivalenol] results in increased expression of NR4A1 mRNA; Colforsin promotes the reaction [Zearalenone results in increased expression of NR4A1 mRNA]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of NR4A1 protein]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of NR4A1 protein] NR4A1 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:8164692 PMID:19822197 PMID:23183170 PMID:26783879 |
|
NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions increases expression |
ISO |
NR4A2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR4A2 protein |
CTD |
PMID:19732956 PMID:19822197 |
|
NCBI chr 3:43,111,258...43,128,391
Ensembl chr 3:43,111,240...43,119,159
|
|
G |
Nr4a3 |
nuclear receptor subfamily 4, group A, member 3 |
multiple interactions |
ISO |
NR4A3 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:19822197 |
|
NCBI chr 5:63,781,801...63,822,890
Ensembl chr 5:63,781,801...63,821,637
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
affects expression |
ISO |
Colforsin affects the expression of NR5A1 mRNA |
CTD |
PMID:20726872 |
|
NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions increases expression |
ISO |
alitretinoin inhibits the reaction [NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA]]; NR5A2 protein promotes the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of CYP19A1 mRNA] Colforsin results in increased expression of NR5A2 mRNA |
CTD |
PMID:16357189 |
|
NCBI chr13:53,750,470...53,870,288
Ensembl chr13:53,750,473...53,870,428
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA; U 0126 inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of NRG1 mRNA] |
CTD |
PMID:21047912 |
|
NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
|
|
G |
Ntf3 |
neurotrophin 3 |
increases expression |
EXP |
Colforsin results in increased expression of NTF3 protein |
CTD |
PMID:19854260 |
|
NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
|
|
G |
Numa1 |
nuclear mitotic apparatus protein 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of NUMA1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:167,044,544...167,091,453
Ensembl chr 1:167,051,209...167,091,453
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
ISO |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of OXT mRNA] |
CTD |
PMID:18936084 |
|
NCBI chr 3:123,106,694...123,107,534
Ensembl chr 3:123,106,694...123,107,534
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in increased cleavage of PARP1 protein] Colforsin results in increased cleavage of PARP1 protein |
CTD |
PMID:9454737 PMID:31278978 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pax8 |
paired box 8 |
increases expression |
ISO |
Colforsin results in increased expression of PAX8 mRNA; Colforsin results in increased expression of PAX8 protein |
CTD |
PMID:15961562 |
|
NCBI chr 3:1,527,316...1,586,019
Ensembl chr 3:1,527,279...1,584,946
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
increases expression multiple interactions |
EXP ISO |
Colforsin results in increased expression of PCK1 mRNA Colforsin inhibits the reaction [Leflunomide results in increased expression of PCK1 mRNA]; Colforsin inhibits the reaction [teriflunomide results in increased expression of PCK1 mRNA] Dexamethasone promotes the reaction [Colforsin results in increased expression of PCK1 mRNA] |
CTD |
PMID:25851902 PMID:30364229 |
|
NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
|
|
G |
Pde1b |
phosphodiesterase 1B |
multiple interactions |
ISO |
PDE1B protein affects the reaction [Colforsin results in increased phosphorylation of PPP1R1B protein] |
CTD |
PMID:12077213 |
|
NCBI chr 7:145,117,951...145,147,711
Ensembl chr 7:145,117,951...145,145,376
|
|
G |
Pde2a |
phosphodiesterase 2A |
multiple interactions |
ISO |
PDE2A protein inhibits the reaction [Colforsin affects the localization of AHR protein] |
CTD |
PMID:17329248 |
|
NCBI chr 1:166,534,643...166,626,158
Ensembl chr 1:166,534,643...166,626,158
|
|
G |
Pde4b |
phosphodiesterase 4B |
increases expression |
ISO |
Colforsin results in increased expression of PDE4B mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 5:121,759,236...122,136,814
Ensembl chr 5:121,952,977...122,136,814
|
|
G |
Pde4d |
phosphodiesterase 4D |
increases expression |
ISO |
Colforsin results in increased expression of PDE4D mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 2:40,219,999...41,468,551
Ensembl chr 2:40,554,146...41,464,264
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
affects response to substance multiple interactions |
ISO |
PDK1 protein affects the susceptibility to Colforsin [PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Colforsin] which affects the abundance of Cyclic AMP] |
CTD |
PMID:28887310 |
|
NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
|
|
G |
Per1 |
period circadian regulator 1 |
multiple interactions increases expression |
ISO |
[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA; AHR protein inhibits the reaction [[Colforsin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of PER1 mRNA]; beta-Naphthoflavone inhibits the reaction [Colforsin results in increased expression of PER1 mRNA] |
CTD |
PMID:23291558 |
|
NCBI chr10:55,681,761...55,696,557
Ensembl chr10:55,687,050...55,695,994
|
|
G |
Pgr |
progesterone receptor |
increases expression |
ISO |
Colforsin results in increased expression of PGR mRNA |
CTD |
PMID:20378682 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of PIAS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 8:67,771,720...67,869,015
Ensembl chr 8:67,771,720...67,869,019
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
PINK1 protein affects the reaction [Colforsin results in decreased expression of DNM1L protein] |
CTD |
PMID:24792327 |
|
NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
multiple interactions |
ISO |
Colforsin inhibits the reaction [IFNG protein promotes the reaction [decitabine results in increased expression of PLA2G2A protein]] |
CTD |
PMID:18953428 |
|
NCBI chr 5:157,282,650...157,285,295
Ensembl chr 5:157,282,669...157,285,328
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
ISO |
PNPLA2 protein affects the reaction [Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 |
|
NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720
|
|
G |
Pnpla6 |
patatin-like phospholipase domain containing 6 |
multiple interactions increases expression |
ISO |
1-Methyl-3-isobutylxanthine promotes the reaction [Colforsin results in increased expression of and results in increased activity of PNPLA6 protein]; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of PNPLA6 mRNA; Colforsin results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein] Colforsin results in increased expression of PNPLA6 mRNA |
CTD |
PMID:20380879 |
|
NCBI chr12:2,068,749...2,098,139
Ensembl chr12:2,069,959...2,097,904
|
|
G |
Pou1f1 |
POU class 1 homeobox 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]; resveratrol inhibits the reaction [Colforsin promotes the reaction [CREB1 protein binds to POU1F1 promoter]] |
CTD |
PMID:23292070 |
|
NCBI chr11:2,645,659...2,662,581
Ensembl chr11:2,645,865...2,662,579
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
Colforsin results in decreased expression of PPARG mRNA |
CTD |
PMID:31278978 |
|
NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Colforsin results in increased expression of PPARGC1A mRNA |
CTD |
PMID:16357189 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ppargc1b |
PPARG coactivator 1 beta |
increases expression |
ISO |
Colforsin results in increased expression of PPARGC1B mRNA |
CTD |
PMID:16357189 |
|
NCBI chr18:56,626,725...56,650,524
Ensembl chr18:56,626,712...56,728,968
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of PPP1R12A protein Capsaicin inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein]; capsazepine inhibits the reaction [Colforsin results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:21474433 |
|
NCBI chr 7:51,404,971...51,515,382
Ensembl chr 7:51,404,919...51,515,373
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
increases phosphorylation multiple interactions |
ISO |
Colforsin results in increased phosphorylation of PPP1R1B protein PDE1B protein affects the reaction [Colforsin results in increased phosphorylation of PPP1R1B protein] |
CTD |
PMID:12077213 |
|
NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
|
|
G |
Prima1 |
proline rich membrane anchor 1 |
increases expression |
EXP |
Colforsin results in increased expression of PRIMA1 mRNA |
CTD |
PMID:18514641 |
|
NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein; PNPLA2 protein affects the reaction [Colforsin results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions increases activity |
EXP ISO |
Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein] Colforsin results in increased activity of PRKACA protein |
CTD |
PMID:16339297 PMID:28601556 |
|
NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein]; [PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein]; PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] |
CTD |
PMID:29669941 |
|
NCBI chr 2:252,602,197...252,691,886
Ensembl chr 2:252,605,307...252,691,886
|
|
G |
Prkar1a |
protein kinase cAMP-dependent type I regulatory subunit alpha |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1A protein] |
CTD |
PMID:29669941 |
|
NCBI chr10:97,940,705...97,959,199
Ensembl chr10:97,940,705...97,957,336
|
|
G |
Prkar1b |
protein kinase cAMP-dependent type I regulatory subunit beta |
multiple interactions |
ISO |
[PRKACB protein mutant form results in increased susceptibility to [Colforsin co-treated with 1-Methyl-3-isobutylxanthine]] results in decreased stability of [PRKACB protein mutant form binds to PRKAR1B protein] |
CTD |
PMID:29669941 |
|
NCBI chr12:17,614,536...17,713,567
Ensembl chr12:17,614,632...17,712,373
|
|
G |
Prkar2a |
protein kinase cAMP-dependent type II regulatory subunit alpha |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of PRKAR2A protein |
CTD |
PMID:25943029 |
|
NCBI chr 8:117,486,085...117,548,768
Ensembl chr 8:117,486,083...117,546,370
|
|
G |
Prl |
prolactin |
multiple interactions increases expression |
EXP ISO |
Colforsin inhibits the reaction [Octreotide results in decreased secretion of PRL protein]; Octreotide inhibits the reaction [Colforsin results in increased expression of PRL protein] [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA; [Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabidiol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Cannabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]; Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased secretion of PRL protein]; Rimonabant inhibits the reaction [Dronabinol inhibits the reaction [[Medroxyprogesterone Acetate co-treated with Estradiol co-treated with Colforsin] results in increased expression of PRL mRNA]] |
CTD |
PMID:1322274 PMID:31154070 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTCH1 mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr17:1,032,242...1,085,885
Ensembl chr17:1,029,048...1,093,873
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
Colforsin promotes the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Colforsin results in increased expression of PTGS2 mRNA bifenthrin inhibits the reaction [Colforsin results in increased expression of PTGS2 mRNA]; Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA] |
CTD |
PMID:11112151 PMID:12493747 PMID:15213229 PMID:17407152 PMID:19063610 PMID:20378682 PMID:21251947 PMID:27590029 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
increases activity multiple interactions |
EXP |
Colforsin results in increased activity of RAP1A protein Rolipram affects the reaction [Colforsin results in increased activity of RAP1A protein] |
CTD |
PMID:10908723 |
|
NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187
|
|
G |
Rap1b |
RAP1B, member of RAS oncogene family |
multiple interactions increases activity |
EXP |
Rolipram affects the reaction [Colforsin results in increased activity of RAP1B protein] |
CTD |
PMID:10908723 |
|
NCBI chr 7:60,850,406...60,878,226
Ensembl chr 7:60,853,930...60,860,990
|
|
G |
Rarres2 |
retinoic acid receptor responder 2 |
multiple interactions |
EXP |
RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP11A1 protein]; RARRES2 protein inhibits the reaction [Colforsin results in increased expression of CYP19A1 protein] |
CTD |
PMID:22948218 |
|
NCBI chr 4:78,205,809...78,208,956
Ensembl chr 4:78,205,812...78,208,767
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[Colforsin co-treated with Theophylline] inhibits the reaction [Etoposide results in decreased phosphorylation of RB1 protein] |
CTD |
PMID:9454737 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Colforsin inhibits the reaction [Morphine results in increased phosphorylation of RELA protein] RELA affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone] |
CTD |
PMID:22258905 PMID:26745512 PMID:27590029 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin promotes the reaction [[AHR protein binds to RELB protein] which binds to CXCL8 promoter]] |
CTD |
PMID:17823304 |
|
NCBI chr 1:80,517,081...80,545,019
Ensembl chr 1:80,517,411...80,544,825
|
|
G |
Ren |
renin |
increases expression multiple interactions increases secretion |
ISO |
Colforsin results in increased expression of REN mRNA [Sodium, Dietary deficiency results in increased susceptibility to Colforsin] which results in increased secretion of REN protein Colforsin results in increased secretion of REN protein |
CTD |
PMID:9256163 PMID:10432392 |
|
NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
|
|
G |
Rnf4 |
ring finger protein 4 |
multiple interactions |
EXP |
[Tetradecanoylphorbol Acetate co-treated with Colforsin] results in increased expression of RNF4 mRNA |
CTD |
PMID:14749358 |
|
NCBI chr14:81,658,400...81,679,756
Ensembl chr14:81,660,354...81,679,082
|
|
G |
Rrp12 |
ribosomal RNA processing 12 homolog |
increases expression |
ISO |
Colforsin results in increased expression of RRP12 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 1:261,106,768...261,140,416
Ensembl chr 1:261,106,760...261,140,389
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
affects splicing multiple interactions |
EXP |
Colforsin affects the splicing of RUNX1 exon HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of RUNX1 exon] |
CTD |
PMID:22684629 |
|
NCBI chr11:32,765,147...33,003,061
Ensembl chr11:32,769,165...33,003,021
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
EXP |
Colforsin results in increased expression of RUNX2 mRNA |
CTD |
PMID:20197312 |
|
NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
[Colforsin co-treated with Rolipram] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein] |
CTD |
PMID:8780174 |
|
NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341
|
|
G |
Selenop |
selenoprotein P |
multiple interactions |
EXP |
Colforsin promotes the reaction [Dexamethasone results in increased expression of SELENOP mRNA] |
CTD |
PMID:18972406 |
|
NCBI chr 2:53,105,912...53,116,198
Ensembl chr 2:53,109,684...53,114,858
|
|
G |
Sesn1 |
sestrin 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of SESN1 mRNA; Colforsin results in decreased expression of SESN1 protein AR protein affects the reaction [Colforsin results in decreased expression of SESN1 protein] |
CTD |
PMID:16751804 |
|
NCBI chr20:46,667,116...46,758,306
Ensembl chr20:46,667,121...46,758,305
|
|
G |
Sftpc |
surfactant protein C |
increases expression |
ISO |
Colforsin results in increased expression of SFTPC mRNA |
CTD |
PMID:2539393 |
|
NCBI chr15:52,211,538...52,214,480
Ensembl chr15:52,211,544...52,214,616
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
SIRT1 mutant form inhibits the reaction [Resveratrol inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]]; SIRT1 protein inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; SIRT1 protein mutant form inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein] Colforsin inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:23292070 PMID:30825513 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
increases expression |
ISO |
Colforsin results in increased expression of SLC26A4 protein |
CTD |
PMID:22811483 |
|
NCBI chr 6:50,809,103...50,848,443
Ensembl chr 6:50,808,923...50,846,965
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SLC2A4 mRNA] |
CTD |
PMID:17407152 |
|
NCBI chr10:56,552,921...56,558,562
Ensembl chr10:56,552,983...56,558,487
|
|
G |
Slc2a5 |
solute carrier family 2 member 5 |
multiple interactions increases expression |
ISO EXP |
Colforsin promotes the reaction [Fructose results in increased expression of SLC2A5 mRNA]; Colforsin promotes the reaction [Glucose results in increased expression of SLC2A5 mRNA] [[Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein] which results in increased uptake of Fructose; [Colforsin results in increased abundance of Cyclic AMP] which results in increased expression of SLC2A5 protein; Colforsin results in increased expression of and results in decreased degradation of SLC2A5 mRNA Colforsin results in increased expression of SLC2A5 mRNA |
CTD |
PMID:8037665 PMID:12820898 |
|
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A1 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr13:110,677,810...110,681,683
Ensembl chr13:110,677,810...110,681,683
|
|
G |
Slc30a2 |
solute carrier family 30 member 2 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A2 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr 5:152,559,577...152,571,800
Ensembl chr 5:152,559,577...152,571,799
|
|
G |
Slc30a4 |
solute carrier family 30 member 4 |
increases expression |
ISO |
Colforsin results in increased expression of SLC30A4 mRNA |
CTD |
PMID:16503475 |
|
NCBI chr 3:114,805,919...114,828,154
Ensembl chr 3:114,805,922...114,828,154
|
|
G |
Slc30a7 |
solute carrier family 30 member 7 |
decreases expression |
ISO |
Colforsin results in decreased expression of SLC30A7 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:218,888,431...218,951,030
Ensembl chr 2:218,888,431...218,951,030
|
|
G |
Slc45a2 |
solute carrier family 45, member 2 |
increases expression |
ISO |
Colforsin results in increased expression of SLC45A2 mRNA |
CTD |
PMID:17460731 |
|
NCBI chr 2:60,966,671...60,999,398
Ensembl chr 2:60,966,789...60,999,398
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions increases expression |
ISO EXP |
Colforsin inhibits the reaction [[Tretinoin co-treated with Hydrocortisone] results in increased activity of SLC5A5 protein] Colforsin results in increased expression of SLC5A5 mRNA; Colforsin results in increased expression of SLC5A5 protein |
CTD |
PMID:16439463 PMID:16954431 |
|
NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
EXP |
Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of SMO mRNA] |
CTD |
PMID:27590029 |
|
NCBI chr 4:57,019,941...57,041,779
Ensembl chr 4:57,019,941...57,042,770
|
|
G |
Snap25 |
synaptosome associated protein 25 |
affects splicing multiple interactions |
EXP |
Colforsin affects the splicing of SNAP25 exon Colforsin promotes the reaction [HNRNPK protein binds to SNAP25 exon]; HNRNPA1 mutant form inhibits the reaction [Colforsin affects the splicing of SNAP25 exon]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin affects the splicing of SNAP25 exon] |
CTD |
PMID:22684629 |
|
NCBI chr 3:129,697,408...129,788,417
Ensembl chr 3:129,599,353...129,788,400
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions increases expression |
ISO |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] Colforsin results in increased expression of SOCS3 protein 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein] |
CTD |
PMID:17407152 PMID:23782265 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD1 protein] |
CTD |
PMID:32092105 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions increases activity |
ISO |
Colforsin results in increased expression of SOD2 mRNA [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA; [EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [[EGF co-treated with Colforsin co-treated with Rotenone] results in increased expression of SOD2 protein] Colforsin results in increased activity of SOD2 protein |
CTD |
PMID:12093828 PMID:32092105 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Spcs3 |
signal peptidase complex subunit 3 |
increases expression |
ISO |
Colforsin results in increased expression of SPCS3 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr16:40,050,862...40,056,296
Ensembl chr16:40,050,734...40,058,822
|
|
G |
Sqstm1 |
sequestosome 1 |
increases degradation |
ISO |
Colforsin results in increased degradation of SQSTM1 protein |
CTD |
PMID:25943029 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srd5a1 |
steroid 5 alpha-reductase 1 |
increases expression |
ISO |
Colforsin results in increased expression of SRD5A1 mRNA |
CTD |
PMID:22461451 |
|
NCBI chr 1:36,320,504...36,354,694
Ensembl chr 1:36,320,461...36,354,756
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
Colforsin inhibits the reaction [Caffeine results in increased expression of SREBF2 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 7:123,381,082...123,438,605
Ensembl chr 7:123,381,077...123,438,603
|
|
G |
Sst |
somatostatin |
multiple interactions |
ISO |
[SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr11:80,358,172...80,359,449
Ensembl chr11:80,358,211...80,359,444
|
|
G |
Sstr2 |
somatostatin receptor 2 |
multiple interactions |
ISO |
[64Cu-CB-TE2A-Y3-TATE co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP]; [SST protein co-treated with SSTR2 protein] inhibits the reaction [Colforsin results in increased chemical synthesis of Cyclic AMP] |
CTD |
PMID:22056254 |
|
NCBI chr10:102,136,283...102,143,449
Ensembl chr10:102,136,283...102,143,434
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO EXP |
BMP6 protein inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Valproic Acid inhibits the reaction [Colforsin results in increased expression of STAR mRNA] [Colforsin co-treated with deoxynivalenol] results in increased expression of STAR mRNA; Colforsin affects the reaction [Zearalenone results in increased expression of STAR mRNA]; NR4A1 protein inhibits the reaction [Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; Ryanodine inhibits the reaction [Colforsin results in increased expression of STAR protein]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR mRNA]; W 7 inhibits the reaction [Colforsin results in increased expression of STAR protein] Colforsin results in increased expression of STAR mRNA; Colforsin results in increased expression of STAR protein [Atrazine co-treated with Colforsin] results in increased expression of STAR mRNA |
CTD |
PMID:14691014 PMID:15967414 PMID:16254025 PMID:16935330 PMID:17080404 PMID:18936084 PMID:20726872 PMID:22461451 PMID:23183170 PMID:25253736 PMID:25765474 PMID:25871633 PMID:26745512 PMID:26783879 PMID:28235592 PMID:28859905 PMID:31100596 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:22446829 |
|
NCBI chr14:22,070,861...22,089,264
Ensembl chr14:22,072,024...22,089,248
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
decreases expression multiple interactions |
ISO |
Colforsin results in decreased expression of SULT2A1 mRNA Hexachlorocyclohexane promotes the reaction [Colforsin results in decreased expression of SULT2A1 mRNA] |
CTD |
PMID:17080404 PMID:22446829 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
decreases expression |
ISO |
Colforsin results in decreased expression of SULT2B1 mRNA |
CTD |
PMID:22446829 |
|
NCBI chr 1:101,712,254...101,774,683
Ensembl chr 1:101,710,959...101,773,508
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]; HU 211 inhibits the reaction [Colforsin promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:15750287 |
|
NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
|
|
G |
Tbr1 |
T-box brain transcription factor 1 |
multiple interactions |
EXP |
Colforsin promotes the reaction [CASK protein modified form binds to TBR1 protein] |
CTD |
PMID:20067577 |
|
NCBI chr 3:47,677,720...47,685,902
Ensembl chr 3:47,677,720...47,685,902
|
|
G |
Testin |
testin gene |
affects expression |
EXP |
Colforsin affects the expression of TESTIN mRNA |
CTD |
PMID:11090432 |
|
NCBI chr17:4,194,796...4,225,376
Ensembl chr17:4,212,890...4,225,376
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
Colforsin inhibits the reaction [Dronabinol results in increased expression of TGFB1 protein]; TGFB1 protein inhibits the reaction [Colforsin results in increased expression of CYP17A1 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein] |
CTD |
PMID:11779138 PMID:15625562 PMID:27590029 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tgs1 |
trimethylguanosine synthase 1 |
increases expression |
ISO |
Colforsin results in increased expression of TGS1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:16,413,356...16,446,881
Ensembl chr 5:16,413,356...16,446,881
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions increases activity increases expression |
EXP |
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol inhibits the reaction [Colforsin results in increased expression of TH mRNA]; bisindolylmaleimide I inhibits the reaction [Colforsin results in increased expression of TH mRNA]; HU 211 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; KT 5720 inhibits the reaction [Colforsin results in increased expression of TH mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of TH mRNA] Colforsin results in increased activity of TH protein Colforsin results in increased expression of TH mRNA; Colforsin results in increased expression of TH protein |
CTD |
PMID:9288946 PMID:14550852 PMID:18992715 |
|
NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Colforsin results in increased expression of TIMP1 mRNA |
CTD |
PMID:20378682 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions increases expression |
EXP |
Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of TIMP2 protein] Colforsin results in increased expression of TIMP2 protein |
CTD |
PMID:21832167 |
|
NCBI chr10:107,338,465...107,386,072
Ensembl chr10:107,338,465...107,386,072
|
|
G |
Tmem50a |
transmembrane protein 50A |
increases expression |
ISO |
Colforsin results in increased expression of TMEM50A mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:153,233,965...153,252,006
Ensembl chr 5:153,233,962...153,252,021
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Colforsin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNF mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of CCL5 mRNA]; Colforsin inhibits the reaction [TNF protein results in increased expression of ICAM1 mRNA] [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]; Colforsin inhibits the reaction [3,4-dihydroxyphenylethanol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Colforsin inhibits the reaction [Shiga Toxin results in increased expression of TNF mRNA]; Colforsin promotes the reaction [TNF protein results in increased expression of IL6 mRNA] Colforsin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]; Colforsin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] Colforsin results in decreased expression of TNF protein |
CTD |
PMID:8780174 PMID:10495789 PMID:10996031 PMID:11675405 PMID:12509806 PMID:15081246 PMID:17407152 PMID:20388727 PMID:21803157 PMID:24771768 PMID:25866079 PMID:27590029 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tob1 |
transducer of ErbB-2.1 |
increases expression |
ISO |
Colforsin results in increased expression of TOB1 mRNA |
CTD |
PMID:15313392 |
|
NCBI chr10:81,913,689...81,915,727
Ensembl chr10:81,913,689...81,915,716
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
Colforsin results in increased expression of TP53 protein |
CTD |
PMID:10642304 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP ISO |
Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1] Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1 protein]; Colforsin promotes the reaction [Capsaicin results in increased activity of TRPV1] |
CTD |
PMID:12886029 PMID:17913835 |
|
NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
|
|
G |
Txnip |
thioredoxin interacting protein |
increases activity |
EXP |
Colforsin results in increased activity of TXNIP mRNA |
CTD |
PMID:21832250 |
|
NCBI chr 2:198,683,168...198,686,971
Ensembl chr 2:198,683,159...198,686,974
|
|
G |
Tyr |
tyrosinase |
increases activity decreases expression increases expression multiple interactions |
ISO |
Colforsin results in increased activity of TYR protein Colforsin results in decreased expression of TYR protein Colforsin results in increased expression of TYR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Colforsin results in increased expression of TYR protein]; [Colforsin co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Colforsin co-treated with Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] results in decreased expression of TYR protein; [Wortmannin co-treated with 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one] promotes the reaction [Colforsin results in increased expression of TYR protein] Colforsin results in increased expression of TYR mRNA [resveratrol co-treated with Colforsin] results in decreased activity of TYR protein; [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYR mRNA]; Colforsin results in increased expression of and results in increased activity of TYR protein; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYR mRNA] |
CTD |
PMID:17460731 PMID:23700242 PMID:28601556 PMID:28849034 |
|
NCBI chr 1:151,012,598...151,106,802
Ensembl chr 1:151,012,598...151,106,802
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression multiple interactions |
ISO |
Colforsin results in increased expression of TYRP1 mRNA; Colforsin results in increased expression of TYRP1 protein [Zinc analog co-treated with Copper analog] inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA]; Particulate Matter inhibits the reaction [Colforsin results in increased expression of TYRP1 mRNA] |
CTD |
PMID:17460731 PMID:23700242 PMID:28601556 |
|
NCBI chr 5:98,387,291...98,406,083
Ensembl chr 5:98,387,291...98,406,083
|
|
G |
Ube2j1 |
ubiquitin-conjugating enzyme E2, J1 |
increases expression |
ISO |
Colforsin results in increased expression of UBE2J1 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 5:48,274,387...48,292,699
Ensembl chr 5:48,274,477...48,290,658
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [Colforsin results in increased metabolism of Lipids]; USF1 protein affects the reaction [Colforsin results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:89,797,750...89,805,561
Ensembl chr13:89,797,800...89,805,558
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation |
ISO |
Colforsin results in increased phosphorylation of VASP protein |
CTD |
PMID:18182247 |
|
NCBI chr 1:80,170,608...80,185,882
Ensembl chr 1:80,170,619...80,185,882
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
Colforsin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Colforsin results in increased expression of VEGFA mRNA] |
CTD |
PMID:10788502 PMID:19063610 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
VIM affects the reaction [[monobutyl phthalate co-treated with Colforsin] results in increased secretion of Progesterone] |
CTD |
PMID:26745512 |
|
NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
|
|
G |
Wt1 |
WT1 transcription factor |
increases expression |
ISO |
Colforsin results in increased expression of WT1 mRNA |
CTD |
PMID:15961562 |
|
NCBI chr 3:95,133,221...95,180,574
Ensembl chr 3:95,133,713...95,180,564
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
[[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein] which results in decreased susceptibility to Cisplatin; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP mRNA; [Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of XIAP protein |
CTD |
PMID:21255191 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Zbtb10 |
zinc finger and BTB domain containing 10 |
decreases expression |
ISO |
Colforsin results in decreased expression of ZBTB10 mRNA |
CTD |
PMID:16751804 |
|
NCBI chr 2:94,692,939...94,730,976
Ensembl chr 2:94,692,939...94,730,978
|
|
G |
Zfp36l1 |
zinc finger protein 36, C3H type-like 1 |
increases expression |
EXP |
Colforsin results in increased expression of ZFP36L1 mRNA |
CTD |
PMID:23423171 |
|
NCBI chr 6:103,308,032...103,313,074
Ensembl chr 6:103,308,045...103,313,074
|
|
G |
Zfp36l2 |
zinc finger protein 36, C3H type-like 2 |
decreases expression |
ISO |
Colforsin results in decreased expression of ZFP36L2 mRNA |
CTD |
PMID:15967414 |
|
NCBI chr 6:7,417,416...7,423,447
Ensembl chr 6:7,417,425...7,421,456
|
|
|
G |
Ache |
acetylcholinesterase |
decreases activity affects binding multiple interactions affects activity |
ISO EXP |
Donepezil results in decreased activity of ACHE protein Donepezil binds to ACHE protein Donepezil inhibits the reaction [Celecoxib results in increased activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein] ALB protein affects the reaction [Donepezil results in decreased activity of ACHE protein]; Donepezil binds to and results in decreased activity of ACHE protein; Donepezil inhibits the reaction [asoxime chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]]; Donepezil inhibits the reaction [Obidoxime Chloride metabolite results in decreased activity of ACHE protein]; Donepezil promotes the reaction [Obidoxime Chloride inhibits the reaction [Sarin results in decreased activity of ACHE protein]] Donepezil affects the activity of ACHE protein AFDX 384 affects the reaction [Donepezil affects the activity of ACHE protein]; Donepezil inhibits the reaction [Streptozocin results in increased activity of ACHE protein] |
CTD |
PMID:9228650 PMID:12111444 PMID:12589378 PMID:14535624 PMID:15135892 PMID:18061284 PMID:18208924 PMID:18343489 PMID:18571635 PMID:19345205 PMID:19705549 PMID:23060470 PMID:25522658 PMID:26902639 PMID:27238725 PMID:30481507 PMID:31176713 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
ALB protein affects the reaction [Donepezil results in decreased activity of ACHE protein] |
CTD |
PMID:26902639 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
App |
amyloid beta precursor protein |
increases abundance decreases response to substance multiple interactions |
ISO EXP |
Donepezil results in increased abundance of APP protein Donepezil results in decreased susceptibility to APP protein Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein alternative form]; Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in increased expression of APP protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein] Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of APP protein] |
CTD |
PMID:18061284 PMID:18571635 PMID:24189446 PMID:28734741 PMID:30481507 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 1:21,525,421...21,537,872
Ensembl chr 1:21,525,421...21,537,863
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Streptozocin results in increased expression of BACE1 protein] |
CTD |
PMID:30481507 |
|
NCBI chr 8:50,140,092...50,162,388
Ensembl chr 8:50,139,997...50,162,361
|
|
G |
Bche |
butyrylcholinesterase |
decreases activity |
ISO EXP |
Donepezil results in decreased activity of BCHE protein |
CTD |
PMID:16036213 PMID:18656440 PMID:19345205 |
|
NCBI chr 2:171,104,476...171,196,186
Ensembl chr 2:171,100,140...171,196,395
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of BCL2 protein] |
CTD |
PMID:19345205 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO EXP |
Donepezil results in increased activity of CASP3 protein Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of CASP3 protein] |
CTD |
PMID:19345205 PMID:20522977 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Donepezil results in increased activity of CASP8 protein |
CTD |
PMID:20522977 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Donepezil results in increased activity of CASP9 protein |
CTD |
PMID:20522977 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:30481507 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions affects expression |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of EGR1 protein] EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of EGR1 mRNA; Donepezil affects the expression of EGR1 protein |
CTD |
PMID:29133030 PMID:32174113 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
F3 |
coagulation factor III, tissue factor |
affects expression |
ISO |
Donepezil affects the expression of F3 mRNA; Donepezil affects the expression of F3 protein |
CTD |
PMID:32174113 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fiz1 |
FLT3-interacting zinc finger 1 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 1:72,379,705...72,387,301
Ensembl chr 1:72,380,711...72,387,301
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of FOS protein] |
CTD |
PMID:29133030 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions affects expression |
ISO |
EGR1 protein affects the reaction [Donepezil affects the expression of ICAM1 protein] Donepezil affects the expression of ICAM1 mRNA; Donepezil affects the expression of ICAM1 protein |
CTD |
PMID:32174113 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL10]] |
CTD |
PMID:26114860 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL13]] |
CTD |
PMID:26114860 |
|
NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL1B protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL1B protein] |
CTD |
PMID:26114860 PMID:30481507 PMID:31369746 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of ARG1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of CHIL3 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 mRNA]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of FIZ1 protein]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL10]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of IL13]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects expression affects secretion |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of IL6 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of IL6 protein] Donepezil affects the expression of IL6 mRNA Donepezil affects the secretion of IL6 protein |
CTD |
PMID:26114860 PMID:30481507 PMID:31369746 PMID:32174113 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Scopolamine results in decreased expression of JUN protein] |
CTD |
PMID:29133030 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of MAPK8 protein] |
CTD |
PMID:19345205 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of MAPK9 protein] |
CTD |
PMID:19345205 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
ISO |
Donepezil results in decreased expression of MMP9 protein Donepezil results in decreased expression of and results in decreased activity of MMP9 protein |
CTD |
PMID:21750701 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Donepezil inhibits the reaction [Streptozocin results in increased activity of MPO protein] |
CTD |
PMID:23060470 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [APP protein modified form results in increased expression of NOS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of NOS2 protein] |
CTD |
PMID:24189446 PMID:31369746 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
ISO |
Donepezil results in decreased expression of NPPB protein |
CTD |
PMID:19879468 |
|
NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
affects expression |
ISO |
Donepezil affects the expression of OLR1 mRNA; Donepezil affects the expression of OLR1 protein |
CTD |
PMID:32174113 |
|
NCBI chr 4:163,239,853...163,261,937
Ensembl chr 4:163,239,849...163,261,958
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression multiple interactions affects expression |
ISO |
Donepezil results in decreased expression of PTGS1 mRNA [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 mRNA; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS1 protein; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Donepezil] results in increased expression of PTGS1 protein; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 mRNA; [Sodium Fluoride co-treated with Rivastigmine co-treated with Donepezil] results in increased expression of PTGS1 protein Donepezil affects the expression of PTGS1 protein |
CTD |
PMID:29777723 |
|
NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO |
[Donepezil co-treated with Rivastigmine] results in decreased expression of PTGS2 protein; [Rivastigmine co-treated with Donepezil] results in decreased expression of PTGS2 mRNA Donepezil inhibits the reaction [APP protein modified form results in increased expression of PTGS2 protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of PTGS2 protein] Donepezil results in decreased expression of PTGS2 mRNA; Donepezil results in decreased expression of PTGS2 protein |
CTD |
PMID:24189446 PMID:29777723 PMID:31369746 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Donepezil inhibits the reaction [APP protein modified form affects the localization of RELA protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of RELA protein] |
CTD |
PMID:24189446 PMID:31369746 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD1 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] results in decreased expression of SOD3 mRNA] |
CTD |
PMID:28734741 |
|
NCBI chr14:60,958,583...60,971,143
Ensembl chr14:60,958,592...60,964,324
|
|
G |
Stat6 |
signal transducer and activator of transcription 6 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased phosphorylation of STAT6 protein]] |
CTD |
PMID:26114860 |
|
NCBI chr 7:70,946,228...70,963,542
Ensembl chr 7:70,946,228...70,964,484
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium inhibits the reaction [IL4 protein results in increased expression of TGFB2]] |
CTD |
PMID:26114860 |
|
NCBI chr13:105,039,639...105,142,010
Ensembl chr13:105,039,853...105,141,030
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions affects expression affects secretion |
ISO EXP |
Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF mRNA]; Donepezil inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Donepezil inhibits the reaction [APP protein modified form results in increased expression of TNF protein]; Donepezil inhibits the reaction [Streptozocin results in increased expression of TNF protein]; Donepezil inhibits the reaction [Valproic Acid results in increased expression of TNF protein] Donepezil affects the expression of TNF mRNA Donepezil affects the secretion of TNF protein |
CTD |
PMID:24189446 PMID:26114860 PMID:30481507 PMID:31369746 PMID:32174113 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in increased expression of TP53 protein] |
CTD |
PMID:19345205 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
EXP |
Donepezil inhibits the reaction [Hydrogen Peroxide results in decreased expression of XIAP protein] |
CTD |
PMID:19345205 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
|
G |
Ca3 |
carbonic anhydrase 3 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA3 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:88,126,519...88,136,063
Ensembl chr 2:88,126,667...88,135,410
|
|
G |
Car2 |
carbonic anhydrase 2 |
multiple interactions |
ISO |
dorzolamide binds to and results in decreased activity of CA2 protein |
CTD |
PMID:17826101 |
|
NCBI chr 2:88,097,740...88,112,868
Ensembl chr 2:88,097,720...88,113,029
|
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate] |
CTD |
PMID:18829547 PMID:19232821 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation |
ISO |
Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein |
CTD |
PMID:23707608 |
|
NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
ISO |
[Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein |
CTD |
PMID:27738319 |
|
NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:21195724 PMID:30623574 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
|
|
G |
Areg |
amphiregulin |
affects response to substance |
ISO |
AREG protein affects the susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:18980991 |
|
NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
decreases response to substance |
ISO |
ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of ATF4 protein |
CTD |
PMID:24768708 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg5 |
autophagy related 5 |
decreases response to substance increases expression |
ISO |
ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased expression of ATG5 protein |
CTD |
PMID:21655094 PMID:23917044 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of ATG7 protein |
CTD |
PMID:21655094 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA] Erlotinib Hydrochloride results in increased expression of ATR mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance multiple interactions |
ISO |
AXL results in decreased susceptibility to Erlotinib Hydrochloride [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [MP470 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:22751098 |
|
NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein] |
CTD |
PMID:25895606 PMID:29274334 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein] |
CTD |
PMID:23894143 PMID:29274334 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] |
CTD |
PMID:30171258 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein] |
CTD |
PMID:23894143 |
|
NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
|
|
G |
Becn1 |
beclin 1 |
decreases response to substance |
ISO |
BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23917044 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [betulinic acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein] |
CTD |
PMID:25895606 PMID:29274334 PMID:30136359 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] |
CTD |
PMID:25981168 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein |
CTD |
PMID:23548265 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity |
ISO |
Erlotinib Hydrochloride results in increased cleavage of CASP3 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein Erlotinib Hydrochloride results in increased activity of CASP3 protein Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein] |
CTD |
PMID:23125191 PMID:25895606 PMID:30171258 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] |
CTD |
PMID:19168569 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd69 |
Cd69 molecule |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of CD69 protein |
CTD |
PMID:21195724 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions decreases expression |
ISO EXP |
Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein] |
CTD |
PMID:22223758 PMID:24768708 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein |
CTD |
PMID:21195724 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions decreases expression |
ISO |
betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein] |
CTD |
PMID:30136359 |
|
NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA] |
CTD |
PMID:29274334 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Chfr |
checkpoint with forkhead and ring finger domains |
multiple interactions |
ISO |
CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride] |
CTD |
PMID:20705357 |
|
NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
|
|
G |
Chrdl2 |
chordin-like 2 |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein |
CTD |
PMID:24979617 |
|
NCBI chr 1:165,008,997...165,036,431
Ensembl chr 1:165,008,912...165,036,435
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases secretion |
ISO |
Erlotinib Hydrochloride results in increased secretion of CSF3 protein |
CTD |
PMID:27738319 |
|
NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions decreases expression |
ISO |
[betulinic acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein |
CTD |
PMID:30136359 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein |
CTD |
PMID:24979617 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein |
CTD |
PMID:26141389 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA |
CTD |
PMID:30364229 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression decreases activity |
ISO |
Erlotinib Hydrochloride results in increased expression of CYP3A4 mRNA Erlotinib Hydrochloride results in decreased activity of CYP3A4 protein |
CTD |
PMID:18839173 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
increases response to substance |
ISO |
CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of DDIT3 protein DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] |
CTD |
PMID:24768708 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dennd6b |
DENN domain containing 6B |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 7:130,162,728...130,178,282
Ensembl chr 7:130,164,675...130,176,696
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO EXP |
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:21613822 PMID:21787763 PMID:22553343 PMID:25625231 PMID:27427493 PMID:30364229 |
|
NCBI chr 2:68,820,616...68,895,537
|
|
G |
Egfr |
epidermal growth factor receptor |
affects response to substance decreases expression decreases phosphorylation decreases activity multiple interactions decreases response to substance |
ISO |
EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein Erlotinib Hydrochloride results in decreased activity of EGFR protein [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:12907618 PMID:16407879 PMID:16891461 PMID:19168569 PMID:21080748 PMID:21541241 PMID:21787763 PMID:22223758 PMID:22751098 PMID:23099361 PMID:23440206 PMID:23548265 PMID:23894143 PMID:25625231 PMID:26455392 PMID:28101945 PMID:30136359 PMID:30364229 PMID:30623574 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form |
CTD |
PMID:24768708 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:25625231 PMID:30364229 |
|
NCBI chr X:1,287,875...1,304,822
Ensembl chr X:1,297,099...1,304,822
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases response to substance |
ISO |
ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
|
|
G |
Foxg1 |
forkhead box G1 |
multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein] Erlotinib Hydrochloride results in decreased expression of FOXG1 protein |
CTD |
PMID:26455392 |
|
NCBI chr 6:69,971,227...69,974,037
Ensembl chr 6:69,971,227...69,974,037
|
|
G |
Foxo3 |
forkhead box O3 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein |
CTD |
PMID:23099361 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein |
CTD |
PMID:24979617 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of GMPR mRNA |
CTD |
PMID:27720938 |
|
NCBI chr17:19,543,274...19,580,929
Ensembl chr17:19,543,275...19,580,929
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form |
CTD |
PMID:30136359 |
|
NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form] |
CTD |
PMID:25895606 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib] |
CTD |
PMID:22553343 |
|
NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
|
|
G |
Ifitm3 |
interferon induced transmembrane protein 3 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 1:213,810,712...213,811,821
Ensembl chr 1:213,810,696...213,811,901
|
|
G |
Ifng |
interferon gamma |
decreases secretion |
ISO |
Erlotinib Hydrochloride results in decreased secretion of IFNG protein |
CTD |
PMID:21195724 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il17f |
interleukin 17F |
increases expression |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL17F mRNA |
CTD |
PMID:24768708 |
|
NCBI chr 9:26,885,702...26,897,219
Ensembl chr 9:26,885,708...26,897,219
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA Erlotinib Hydrochloride results in increased secretion of IL1B protein |
CTD |
PMID:27738319 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il1r2 |
interleukin 1 receptor type 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 9:46,840,646...46,881,241
Ensembl chr 9:46,840,992...46,881,264
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA |
CTD |
PMID:27738319 |
|
NCBI chr11:77,456,648...77,593,208
Ensembl chr11:77,463,954...77,593,207
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein |
CTD |
PMID:27738319 |
|
NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
|
|
G |
Il2 |
interleukin 2 |
decreases secretion |
ISO |
Erlotinib Hydrochloride results in decreased secretion of IL2 protein |
CTD |
PMID:21195724 |
|
NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
|
|
G |
Il25 |
interleukin 25 |
increases expression |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL25 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr15:33,594,852...33,599,692
Ensembl chr15:33,596,301...33,599,685
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of IL2RA protein |
CTD |
PMID:21195724 |
|
NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
|
|
G |
Il6 |
interleukin 6 |
increases expression increases secretion multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in increased expression of IL6 mRNA Erlotinib Hydrochloride results in increased secretion of IL6 protein Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein] |
CTD |
PMID:24768708 PMID:27738319 PMID:30623574 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr X:156,716,469...156,726,367
Ensembl chr X:156,716,604...156,725,977
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
EXP |
Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein |
CTD |
PMID:23894143 |
|
NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects activity |
ISO |
Erlotinib Hydrochloride affects the activity of KCNH2 protein |
CTD |
PMID:23707608 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein |
CTD |
PMID:24979617 |
|
NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
increases response to substance |
ISO |
KRAS protein results in increased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:20705357 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
Erlotinib Hydrochloride promotes the reaction [betulinic acid results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:30136359 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO EXP |
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased expression of MCL1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein] |
CTD |
PMID:25895606 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
multiple interactions decreases phosphorylation |
ISO |
[Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein Erlotinib Hydrochloride results in decreased phosphorylation of MET protein |
CTD |
PMID:21106725 PMID:23894143 |
|
NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
|
|
G |
Micb |
MHC class I polypeptide-related sequence B |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of MICB protein |
CTD |
PMID:21951556 |
|
NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] |
CTD |
PMID:19661247 |
|
NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Msmo1 |
methylsterol monooxygenase 1 |
decreases response to substance multiple interactions |
ISO |
MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form] |
CTD |
PMID:23125191 |
|
NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:21655094 PMID:25895606 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA] |
CTD |
PMID:18006877 PMID:19661247 |
|
NCBI chr 1:214,725,482...214,756,653
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nol10 |
nucleolar protein 10 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 6:42,656,661...42,745,099
Ensembl chr 6:42,656,616...42,745,098
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions decreases response to substance increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased expression of NOX4 protein |
CTD |
PMID:23917044 |
|
NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:18839173 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
affects localization |
ISO |
Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form |
CTD |
PMID:30364229 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nsdhl |
NAD(P) dependent steroid dehydrogenase-like |
decreases response to substance |
ISO |
NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr X:152,933,118...152,964,399
Ensembl chr X:152,933,069...152,964,390
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein |
CTD |
PMID:24979617 |
|
NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride results in increased cleavage of PARP1 protein [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:23125191 PMID:25895606 PMID:30171258 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression decreases response to substance increases localization |
ISO |
Erlotinib Hydrochloride results in increased expression of PML protein PML protein results in decreased susceptibility to Erlotinib Hydrochloride Erlotinib Hydrochloride results in increased localization of PML protein |
CTD |
PMID:23440206 |
|
NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Ptpn9 |
protein tyrosine phosphatase, non-receptor type 9 |
decreases expression decreases response to substance |
ISO |
Erlotinib Hydrochloride results in decreased expression of PTPN9 protein PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23894143 |
|
NCBI chr 8:61,658,851...61,739,458
Ensembl chr 8:61,659,445...61,739,434
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein |
CTD |
PMID:23548265 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein |
CTD |
PMID:23548265 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein |
CTD |
PMID:21195724 |
|
NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of RB1 protein modified form] |
CTD |
PMID:21195724 PMID:30136359 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein] |
CTD |
PMID:28101945 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation decreases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form] |
CTD |
PMID:23125191 PMID:23440206 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:21655094 PMID:25895606 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
Selenbp1 |
selenium binding protein 1 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:196,105,592...196,146,474
Ensembl chr 2:196,105,569...196,113,149
|
|
G |
Siah2 |
siah E3 ubiquitin protein ligase 2 |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:148,874,151...148,891,900
Ensembl chr 2:148,874,151...148,891,900
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA |
CTD |
PMID:29274334 |
|
NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA |
CTD |
PMID:24768708 |
|
NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions decreases expression |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein] Erlotinib Hydrochloride results in decreased expression of SOX9 protein |
CTD |
PMID:26455392 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Erlotinib Hydrochloride results in increased expression of SQSTM1 protein |
CTD |
PMID:30136359 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
decreases phosphorylation |
ISO |
Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein |
CTD |
PMID:23894143 |
|
NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases phosphorylation decreases expression increases response to substance decreases response to substance multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride [betulinic acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:23125191 PMID:23894143 PMID:30136359 |
|
NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
|
|
G |
Tent5c |
terminal nucleotidyltransferase 5C |
decreases expression |
ISO |
Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA |
CTD |
PMID:27720938 |
|
NCBI chr 2:202,797,766...202,816,562
Ensembl chr 2:202,798,198...202,816,562
|
|
G |
Tfap2a |
transcription factor AP-2 alpha |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] |
CTD |
PMID:21499124 PMID:21951556 |
|
NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
|
|
G |
Tgfa |
transforming growth factor alpha |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib] |
CTD |
PMID:22553343 |
|
NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to gemcitabine]] |
CTD |
PMID:21613822 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tmed2 |
transmembrane p24 trafficking protein 2 |
decreases response to substance |
ISO |
TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride |
CTD |
PMID:23125191 |
|
NCBI chr12:37,471,259...37,480,344
Ensembl chr12:37,471,260...37,480,297
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions |
ISO |
[gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein |
CTD |
PMID:24979617 |
|
NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
|
|
G |
Tollip |
toll interacting protein |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TOLLIP mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein] |
CTD |
PMID:25895606 PMID:29274334 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TRAF6 mRNA |
CTD |
PMID:27738319 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
increases expression decreases response to substance multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of TWIST1 protein TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein] [TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein |
CTD |
PMID:30171258 |
|
NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
|
|
G |
Tyms |
thymidylate synthetase |
decreases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in decreased expression of TYMS protein betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of TYMS protein] |
CTD |
PMID:30136359 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|
G |
Ulbp1 |
UL16 binding protein 1 |
increases expression multiple interactions |
ISO |
Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA] |
CTD |
PMID:21499124 PMID:21951556 |
|
NCBI chr 1:1,181,301...1,200,526
Ensembl chr 1:1,180,932...1,220,916
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
EXP |
Erlotinib Hydrochloride results in increased expression of XBP1 protein modified form |
CTD |
PMID:24768708 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases expression |
ISO |
[Fingolimod Hydrochloride results in increased abundance of 27-hydroxycholesterol] which results in increased expression of ABCA1 mRNA; NPC1 protein affects the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein]; UVI 3003 inhibits the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein] Fingolimod Hydrochloride results in increased expression of ABCA1 mRNA; Fingolimod Hydrochloride results in increased expression of ABCA1 protein |
CTD |
PMID:20056921 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of ACTA2 protein] |
CTD |
PMID:24893116 |
|
NCBI chr 1:252,537,614...252,550,394
Ensembl chr 1:252,537,615...252,550,394
|
|
G |
Adm |
adrenomedullin |
multiple interactions |
EXP |
Fingolimod Hydrochloride promotes the reaction [Mercuric Chloride results in increased expression of ADM mRNA]; Fingolimod Hydrochloride promotes the reaction [Mercuric Chloride results in increased expression of ADM protein] |
CTD |
PMID:15680492 |
|
NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pifithrin inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:25939952 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
Fingolimod Hydrochloride promotes the reaction [APOA1 protein results in increased secretion of Cholesterol] |
CTD |
PMID:20056921 |
|
NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of ATG12 protein |
CTD |
PMID:25939952 |
|
NCBI chr18:40,721,799...40,732,143
Ensembl chr18:40,721,800...40,732,126
|
|
G |
Atg3 |
autophagy related 3 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of ATG3 protein |
CTD |
PMID:25939952 |
|
NCBI chr11:60,585,192...60,613,706
Ensembl chr11:60,585,171...60,613,718
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of ATG5 protein |
CTD |
PMID:25939952 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of ATG7 protein |
CTD |
PMID:25939952 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of BDNF mRNA |
CTD |
PMID:24859201 |
|
NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
BECN1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of BECN1 protein]; Fingolimod Hydrochloride results in increased expression of and results in increased cleavage of BECN1 protein |
CTD |
PMID:25939952 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage |
ISO |
3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP3 protein] Fingolimod Hydrochloride results in increased activity of CASP3 protein |
CTD |
PMID:25939952 PMID:29654831 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
increases cleavage multiple interactions |
ISO |
Fingolimod Hydrochloride results in increased cleavage of CASP8 protein SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP8 protein] |
CTD |
PMID:25939952 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases response to substance increases expression |
ISO |
3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid inhibits the reaction [Fingolimod Hydrochloride results in increased expression of CCL2 protein] CCL2 results in increased susceptibility to Fingolimod Hydrochloride |
CTD |
PMID:23043544 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
Fingolimod Hydrochloride results in decreased expression of CCND1 mRNA Estradiol inhibits the reaction [Fingolimod Hydrochloride results in decreased expression of CCND1 mRNA]; Fingolimod Hydrochloride inhibits the reaction [Estradiol results in decreased expression of CCND1 mRNA] |
CTD |
PMID:29654831 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccng2 |
cyclin G2 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of CCNG2 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr14:16,267,572...16,276,068
Ensembl chr14:16,267,573...16,276,068
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA] |
CTD |
PMID:24893116 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of COL3A1 mRNA] |
CTD |
PMID:24893116 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of COMT mRNA |
CTD |
PMID:29654831 |
|
NCBI chr11:86,715,981...86,735,630
Ensembl chr11:86,715,981...86,735,622
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions decreases expression |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Estradiol results in increased expression of CXCR4 mRNA] Fingolimod Hydrochloride results in decreased expression of CXCR4 mRNA |
CTD |
PMID:29654831 |
|
NCBI chr13:45,314,952...45,318,856
Ensembl chr13:45,314,933...45,318,878
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Fingolimod Hydrochloride results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:29654831 |
|
NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Fingolimod Hydrochloride results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:29654831 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
Fingolimod Hydrochloride results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:29654831 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Estradiol results in increased expression of ESR1 protein] |
CTD |
PMID:29654831 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions decreases expression |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Estradiol results in increased expression of ESR2 protein] Fingolimod Hydrochloride results in decreased expression of ESR2 protein |
CTD |
PMID:29654831 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of FOS mRNA |
CTD |
PMID:24859201 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gnaq |
G protein subunit alpha q |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of GNAQ protein] |
CTD |
PMID:25980589 |
|
NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
|
|
G |
Hdac1 |
histone deacetylase 1 |
affects binding multiple interactions |
ISO |
Fingolimod Hydrochloride metabolite binds to HDAC1 protein Fingolimod Hydrochloride metabolite inhibits the reaction [S1PR1 protein binds to HDAC1 protein]; SPHK2 protein promotes the reaction [Fingolimod Hydrochloride metabolite binds to HDAC1 protein] |
CTD |
PMID:24859201 |
|
NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of HMGCR mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of HMGCS1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:52,427,351...52,445,082
Ensembl chr 2:52,431,601...52,445,055
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of IDI1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr17:57,976,266...57,984,036
Ensembl chr17:57,976,268...57,984,036
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of IL1B protein] |
CTD |
PMID:24893116 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of IL6 protein] |
CTD |
PMID:24893116 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Fingolimod Hydrochloride results in decreased activity of KCNH2 protein |
CTD |
PMID:25223691 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Klhl24 |
kelch-like family member 24 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of KLHL24 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr11:84,613,101...84,643,674
Ensembl chr11:84,615,760...84,633,504
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Fingolimod Hydrochloride results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:25939952 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Fingolimod Hydrochloride results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:25939952 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 mRNA]; Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of MMP9 protein] |
CTD |
PMID:25980589 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
Fingolimod Hydrochloride results in decreased phosphorylation of MTOR protein |
CTD |
PMID:25939952 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Npc1 |
NPC intracellular cholesterol transporter 1 |
multiple interactions increases expression |
ISO |
NPC1 protein affects the reaction [Fingolimod Hydrochloride results in increased expression of ABCA1 protein] Fingolimod Hydrochloride results in increased expression of NPC1 protein |
CTD |
PMID:20056921 |
|
NCBI chr18:3,616,878...3,662,656
Ensembl chr18:3,616,878...3,662,683
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; BECN1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pifithrin inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein] |
CTD |
PMID:25939952 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of PDCD4 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 1:274,616,625...274,648,204
Ensembl chr 1:274,625,224...274,648,204
|
|
G |
Plcb4 |
phospholipase C, beta 4 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of PLCB4 protein] |
CTD |
PMID:25980589 |
|
NCBI chr 3:128,601,163...128,971,720
Ensembl chr 3:128,756,799...128,971,746
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions increases expression |
ISO |
necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased expression of RIPK1 protein] |
CTD |
PMID:25939952 |
|
NCBI chr17:31,537,580...31,569,904
Ensembl chr17:31,537,591...31,569,904
|
|
G |
Ripk3 |
receptor-interacting serine-threonine kinase 3 |
increases expression multiple interactions |
ISO |
Fingolimod Hydrochloride results in increased expression of RIPK3 protein RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] |
CTD |
PMID:25939952 |
|
NCBI chr15:34,470,796...34,479,741
Ensembl chr15:34,470,796...34,479,741
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation |
ISO |
Fingolimod Hydrochloride results in decreased phosphorylation of RPS6KB1 protein |
CTD |
PMID:25939952 |
|
NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions decreases activity decreases expression |
ISO |
Fingolimod Hydrochloride inhibits the reaction [SPHK2 protein results in increased expression of S1PR1 protein]; Fingolimod Hydrochloride metabolite inhibits the reaction [S1PR1 protein binds to HDAC1 protein] Fingolimod Hydrochloride analog results in decreased activity of S1PR1 protein Fingolimod Hydrochloride results in decreased expression of S1PR1 protein [3-amino-4-(3-hexylphenylamino)-4-oxobutylphosphonic acid results in decreased activity of S1PR1 protein] which results in decreased susceptibility to Fingolimod Hydrochloride |
CTD |
PMID:23043544 PMID:24420784 PMID:24859201 |
|
NCBI chr 2:218,654,406...218,658,761
Ensembl chr 2:218,654,554...218,658,761
|
|
G |
S1pr3 |
sphingosine-1-phosphate receptor 3 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [sphingosine 1-phosphate results in increased expression of S1PR3 protein] |
CTD |
PMID:25980589 |
|
NCBI chr17:13,799,383...13,812,877
Ensembl chr17:13,799,383...13,812,704
|
|
G |
Sphk2 |
sphingosine kinase 2 |
multiple interactions increases response to substance increases phosphorylation |
ISO |
Fingolimod Hydrochloride inhibits the reaction [SPHK2 protein results in increased expression of S1PR1 protein]; SPHK2 protein promotes the reaction [Fingolimod Hydrochloride metabolite binds to HDAC1 protein] SPHK2 results in increased susceptibility to Fingolimod Hydrochloride SPHK2 protein results in increased phosphorylation of Fingolimod Hydrochloride |
CTD |
PMID:23043544 PMID:24859201 |
|
NCBI chr 1:101,692,972...101,700,604
Ensembl chr 1:101,692,973...101,697,277
|
|
G |
Sqle |
squalene epoxidase |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of SQLE mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 7:99,609,929...99,624,803
Ensembl chr 7:99,609,191...99,624,732
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP8 protein]; SQSTM1 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein] Fingolimod Hydrochloride results in decreased expression of SQSTM1 protein |
CTD |
PMID:25939952 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
decreases phosphorylation |
ISO |
Fingolimod Hydrochloride results in decreased phosphorylation of TFE3 protein |
CTD |
PMID:29945972 |
|
NCBI chr X:15,574,579...15,587,826
Ensembl chr X:15,575,934...15,587,419
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:24893116 |
|
NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of TNF protein] |
CTD |
PMID:24893116 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; necrostatin-1 inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; pyrazolanthrone inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein]; RIPK3 mutant form inhibits the reaction [Fingolimod Hydrochloride results in increased phosphorylation of TP53 protein] |
CTD |
PMID:25939952 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Fingolimod Hydrochloride inhibits the reaction [Paraquat results in increased expression of VEGFA mRNA] |
CTD |
PMID:24893116 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
Fingolimod Hydrochloride results in increased expression of VEGFD mRNA |
CTD |
PMID:24859201 |
|
NCBI chr X:31,816,480...31,852,239
Ensembl chr X:31,816,436...31,851,715
|
|
|
G |
Slc6a4 |
solute carrier family 6 member 4 |
decreases expression |
EXP |
fluoxetine decreases expression of Slc6a4 mRNA in the dorsal raphe nucleus |
RGD |
PMID:15936043 |
RGD:38549581 |
NCBI chr10:63,153,656...63,188,377
Ensembl chr10:63,153,651...63,176,463
|
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
Lurasidone Hydrochloride binds to and results in decreased activity of DRD2 protein |
CTD |
PMID:20404009 |
|
NCBI chr 8:53,678,777...53,743,643
Ensembl chr 8:53,678,777...53,743,642
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
Lurasidone Hydrochloride binds to and results in increased activity of HTR1A protein |
CTD |
PMID:20404009 |
|
NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
|
|
G |
Htr7 |
5-hydroxytryptamine receptor 7 |
multiple interactions |
ISO |
Lurasidone Hydrochloride binds to and results in decreased activity of HTR7 protein |
CTD |
PMID:20404009 |
|
NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
|
|
|